

Technology Assessment



Technology Assessment
Program

Randomized Trials of Secondary Prevention Programs in Coronary Artery Disease: A Systematic Review

Agency for Healthcare
Research and Quality
540 Gaither Road
Rockville, Maryland 20850

December 2005

FINAL REPORT

This report is based on research conducted by the University of Alberta Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-02-0023). The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this article should be construed as an official position of the Agency for Healthcare Research and Quality or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decision-makers, patients and clinicians, health system leaders, and policymakers, make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients. This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

**RANDOMIZED TRIALS OF SECONDARY PREVENTION
PROGRAMS IN CORONARY ARTERY DISEASE: A SYSTEMATIC
REVIEW**

Prepared For:

Agency for Healthcare Research and Quality
US Department of Health and Human Services
540 Gaither Road
Rockville, MD 20852
<http://www.ahrq.gov>

Contract No. 290-02-0023

Prepared By:

Alexander M Clark, Finlay A McAlister,
Lisa Hartling, Ben Vandermeer,
for the University of Alberta Evidence-based Practice Center
Edmonton, Alberta, Canada

Funding: AC and FMcA are Population Health Investigators of the Alberta Heritage Foundation for Medical Research; FMcA also holds a Canadian Institutes of Health Research New Investigator Award and the Merck Frosst/Aventis Chair in Patient Health Management at the University of Alberta.

Correspondence to: Dr. F. McAlister (Division of General Internal Medicine, 2E3.24 WMC, University of Alberta Hospital, 8440 112 Street, Edmonton, Alberta, Canada T6G 2R7 ; e-mail: Finlay.McAlister@ualberta.ca)

Table of Contents

Summary.....	4
Introduction.....	9
What are Secondary Prevention Programs?.....	10
Rationale for this Review.....	12
Methods.....	14
Results.....	22
Study Selection.....	22
Studies Included.....	23
Data Synthesis.....	24
Methodologic Quality.....	29
Exploring the impact of program components.....	29
Discussion.....	33
Generalizability of the trial data	40
Limitations of this review.....	43
Conclusion.....	45
Acknowledgements.....	46
References.....	48
Box 1 (Modifiable coronary risk factors).....	64
Table 1 (Description of studies included).....	65
Table 2 (Impact on all-cause mortality and recurrent myocardial infarctions).....	71
Table 3 (Impact of interventions on other endpoints.....	74
Table 4 (Methodologic Quality of Included Studies).....	77
Table 5a (Characteristics of Comprehensive Cardiac Rehabilitation Programs).....	79
Table 5b (Characteristics of Group Cardiac Rehabilitation Without Exercise Component Programs).....	80
Table 5c (Characteristics of Individual Counseling Programs).....	81
Table 6 (Number of trials with age-based exclusion criteria)	82
Table 7 (Proportion of women in trials)	83
Figure 1 (Flow of trials through the selection process).....	84
Figure 2 (All-cause mortality in trials evaluating comprehensive cardiac rehabilitation).....	85
Figure 3 (All-cause mortality in trials evaluating group cardiac rehabilitation without exercise component).....	86
Figure 4 (All-cause mortality in trials evaluating individual counseling).....	87

Figure 5 (Recurrent myocardial infarctions in trials evaluating comprehensive cardiac rehabilitation).....	88
Figure 6 (Recurrent myocardial infarctions in trials evaluating group cardiac rehabilitation without exercise component).....	89
Figure 7 (Recurrent myocardial infarctions in trials evaluating individual counseling).....	90
Figure 8 (Hospitalization rates in trials evaluating secondary prevention programs).....	91
Figure 9 (Funnel Plot for all-cause mortality data).....	92
Figure 10 (Survey steps).....	93
Figure 11 (All-cause mortality stratified by length of program).....	94
Figure 12 (All-cause mortality stratified by degree of health care provider specialization).....	95
Figure 13 (Hospitalizations stratified by degree of individualization).....	96
Figure 14 (Hospitalizations by nurse prescribing).....	97
Appendix A (Search Strategy and Results).....	98
Appendix B (List of Excluded Studies and Reasons).....	101
Appendix C (Copy of questions sent to primary study authors).....	126
Appendix D (Missing fields prior to and after author survey).....	127
Appendix E (Results of descriptive survey).....	128

SUMMARY

Background: While it is well established that cardiac rehabilitation programs employing supervised exercise training improve outcomes in survivors of myocardial infarction, the effects of secondary prevention programs which are not primarily exercise-based are unclear.

Objectives: To determine whether secondary prevention programs for patients with established coronary artery disease (CAD) improve health outcomes. To characterize secondary prevention programs which have been evaluated in the literature and to identify any program-related factors which influence effectiveness for patients with established coronary artery disease (CAD). Of note, secondary prevention programs which consisted of exercise training alone were not included in this review.

Design: Randomized clinical trials (RCTs) of secondary prevention programs in patients with CAD were identified by searching Medline 1966-2004; the Cochrane Central Register of Controlled Trials, Issue 4, 2004; Embase 1980-2004; CINAHL 1982-2004; SIGLE 1980-2004; the Cochrane Effective Practice and Organization of Care Study Registry; bibliographies of published

studies, and via contact with experts in the field and references provided by the Centers for Medicare and Medicaid Services and authors of the primary studies. Studies were excluded if the program being evaluated consisted of supervised exercise training only; studies were selected and data extracted independently by 2 investigators, and summary risk ratios were calculated using the random effects model. Each intervention was classified *a priori* into one of 3 groups: (1) *Comprehensive Cardiac Rehabilitation* (those interventions which consist of exercise training plus group education and counseling sessions about coronary risk factor management), (2) *Group Cardiac Rehabilitation without exercise component* (programs which include group education and counseling sessions about coronary risk factor management, but without a structured exercise component), or (3) *Individual Counseling* (programs, usually delivered by specially trained nurses, which involve individual education and counseling sessions with individual follow-up, either in person or by telephone, to encourage coronary risk factor optimization). Primary study authors were contacted for additional details about their programs. The association of program

characteristics with the main outcomes were examined using a forward step-wise meta-regression.

Results: A total of 46 RCTs (18 821 patients with CAD) were identified. The summary RR was 0.87 (95% CI 0.79-0.97) for all-cause mortality in the 29 trials (13 857 patients) reporting this outcome, but this result differed over time with a RR of 0.97 (95% CI 0.82-1.14) for 12 month all-cause mortality in the 19 trials (9393 patients, p for heterogeneity=0.95, I-squared=0%) reporting this timeframe and a RR of 0.53 (95% CI 0.31-0.92) for all-cause mortality at 24 months in the 4 trials (1367 patients, p for heterogeneity=0.44, I-squared=0%) reporting this timeframe. The summary RR was 0.83 (95% CI 0.72-0.96) for recurrent myocardial infarction and 0.84 (95% CI 0.74-0.97) for hospitalization rates over a median follow-up of 12 months. There were no appreciable differences between the 3 types of secondary prevention programs we examined in their effects on mortality, hospitalizations, or recurrent myocardial infarctions. None of the program characteristics demonstrated a significant effect on all-cause mortality or on recurrent myocardial infarctions- indeed, the mortality benefit seen with short-term interventions (less than 10 hours of patient-provider contact time) was similar to the overall

pooled result: RR 0.80, 95% CI 0.68 to 0.95, in 4307 patients from 9 trials. For hospitalizations, programs with increased degrees of individualization exerted greater impacts ($p < 0.001$ in meta-regression, RR 0.74, 95% CI 0.65 to 0.85). Secondary prevention programs had positive impacts on processes of care: patients randomized to these programs were more likely to be prescribed efficacious medications and 22 out of 27 trials evaluating cholesterol profiles demonstrated improvements with these programs compared to usual care (in 14 trials the improvements were statistically significant, with effect sizes in the small to moderate range). Eighteen of the 30 trials evaluating quality of life or functional status reported statistically significantly better outcomes in those patients exposed to the intervention programs, although the effect sizes were generally small. None of these trials were double-blind and Jadad quality scores were clustered around 2. Physicians adopted a coordinating role in only 4 (9%) programs. Only one quarter of the programs were based on specific guidelines. Around one third offered standardized programs, though the greatest proportion of these programs (43%) had some individualization to the degree expected with usual care.

Conclusions: Secondary prevention programs improve processes of care, enhance quality of life/functional status, reduce hospitalizations, reduce recurrent myocardial infarctions, and reduce mortality in patients with established CAD. There is inadequate data to conclusively comment on the incremental benefits of specific components contained within these programs. Though most programs are likely to involve specialist health professionals, physicians adopt an active coordinating role in only a small minority of programs. Programs with more individualization are more effective at reducing hospitalizations and even short-term programs (less than 10 hours of provider-patient contact) demonstrate mortality benefits.

INTRODUCTION

Although cardiovascular death rates in North America have declined over the past two decades,[1] cardiovascular disease remains the most common cause of death (38% of all deaths in the United States in 2002), hospitalization, and physician office visits (over 80 million visits in 2002), and accounts for a large portion of total health care costs in the United States (estimated direct and indirect costs for 2005 are over \$393 billion).[2] Using data from the National Health and Nutrition Examination Survey (NHANES 1999-2002), it is estimated that over 70 million Americans have one or more types of cardiovascular disease and over 13 million have known coronary artery disease (CAD), however, the proportion with undiagnosed disease is likely several fold higher.[2] Indeed, it is estimated that a United States citizen suffers a coronary event every 26 seconds, with 41% dying within a year.[2] Of course, CAD is not a North American phenomenon and atherosclerotic cardiovascular disease is the leading cause of death worldwide.[3] A case-control study in nearly 30,000 subjects from 52 countries confirmed that 9 known coronary risk factors (Box 1) account for over 90% of the

population attributable risks for CAD in both men and women, in all age subgroups, and across all regions.[4]

Control of the CAD epidemic will require a multifaceted strategy that targets the 9 modifiable risk factors identified in the INTERHEART study and includes both primary prevention strategies (some designed for the general population and some targeting only high risk populations) and secondary prevention strategies (targeted at those with established CAD).[5] Despite the abundant evidence base for CAD prevention,[6] health outcomes studies consistently demonstrate suboptimal control of cardiovascular risk factors due to gaps in the application of this evidence to clinical practice that contribute to sub-optimal patient outcomes.[7-15] Furthermore, even when some therapies proven to be efficacious in preventing morbidity and mortality in patients with coronary disease are prescribed, patient compliance may be poor (from 43% to 75% at one year).[16,17] Secondary prevention programs are increasingly advocated as a means to improve management and outcomes for patients with CAD.

What are Secondary Prevention Programs?

In this report, we employ the American Heart Association and the American Association of Cardiovascular and Pulmonary

Rehabilitation definition of a secondary prevention program as one that “incorporates a multifaceted and multidisciplinary approach to overall cardiovascular risk reduction in patients with established coronary artery disease”. [18] Secondary prevention programs may include a number of components to achieve the overall goal of assessing and modifying cardiovascular risk factors in at-risk patients. In order to examine the effects of different types of secondary prevention programs, we a priori defined the following program types: (1) Comprehensive Cardiac Rehabilitation (programs that include exercise with group education and counseling sessions about coronary risk factor management), (2) Group Cardiac Rehabilitation without exercise component (programs that include group education and counseling sessions about coronary risk factor management, but no structured exercise component), or (3) Individual Counseling (programs, usually delivered by specially trained nurses, involving individual education and counseling sessions and individual follow-up, either in person or by telephone, to encourage coronary risk factor optimization).

Rationale for this Review:

While numerous reviews have shown that cardiac rehabilitation programs improve outcomes in MI survivors,[19-23] these conclusions were based largely on trials which tested supervised exercise programs versus no exercise post-MI. As activity levels are inversely proportional to cardiovascular mortality and exercise training confers substantial physiologic and clinical benefits,[24] it is not surprising that trials of exercise programs found positive treatment effects. However, few of the trials included in these reviews evaluated secondary prevention programs that were not primarily exercise-based. To address this gap in the literature, we performed a systematic review- in the 12 trials we identified (with 9803 patients), we found that multidisciplinary non-exercise based programs improved processes of care (namely prescription of proven efficacious secondary prevention therapies) and risk factor profiles, and reduced hospitalizations by 16% (95% confidence interval [CI] 6% to 24%), but did not have an appreciable impact on rates of death (RR 0.91, 95% CI 0.79-1.04) or recurrent myocardial infarction (RR 0.94, 95% CI 0.80-1.10).[25]

As current guidelines recommend that secondary prevention programs should not be restricted to supervised exercise programs

but should rather address the full range of modifiable risk factors,[18] we conducted the current systematic review to expand our earlier work and to determine whether comprehensive secondary prevention programs (in contradistinction to exercise-only or similar single modality programs) prevent coronary events and/or death in patients with CAD.

Systematic reviews incorporating meta-analyses can determine the effectiveness of interventions. However, in pooling different studies the particular characteristics of different interventions tend to be “lost in the mix”[26] and meta-analyses cannot explain why some interventions are more effective than others.[27] To gain a comprehensive overview of the literature on secondary prevention programs, we therefore derived a survey to collect a wide range of additional quantitative and qualitative data on program characteristics from primary study authors. Finally, to identify to what degree program characteristics affect outcomes, we performed a meta-regression to examine the association of *a priori* defined co-variates with our main outcomes.

METHODS

Searching for relevant studies:

We searched the following electronic databases to identify human randomized trials published in English: Medline 1966-2004; Cochrane Central Register of Controlled Trials, Issue 4, 2004; Embase 1980-2004; CINAHL 1982-2004; and, SIGLE 1980-2004. In order to identify recent publications, we also searched PubMed from January 2004 to December 2004 and conducted a cited reference search for our previous systematic review [25] in Web of Science (1999 to 2004). The searches (see Appendix A for listing of search strategy strings and results) were based on the following terms: case management, comprehensive health care, disease management, health services research, home care services, clinical protocols, patient care planning, quality of health care, rehabilitation, nurse led clinics, special clinics, and myocardial ischemia. To identify any studies missed by the literature searches, we hand-searched reference lists of all identified studies, as well as the reference list of a recent related review.[23] Finally, we screened references provided by the Centers for Medicare and Medicaid Services and content experts, including authors of the primary studies.

Selection of studies and abstraction of data:

For the systematic review, two of the investigators (AC and FM) independently reviewed the titles and abstracts of all citations to identify any studies reporting the impact of secondary prevention programs on death, MI, or hospitalization rates in patients with CAD (clinically manifest as angina, MI, or coronary revascularization). The full texts of all potentially relevant articles were obtained and reviewed by both investigators using pre-standardized data abstraction forms and *a priori* defined eligibility criteria. Any discrepancies were resolved by consensus.

All outcome data were extracted by AC and FM independently, and double-checked by BV. Outcomes were assigned according to the intention-to-treat principle and we accepted the definitions for each outcome used by the investigators in the primary studies. Original investigators were contacted to clarify the published data: 27 of the 31 study authors contacted provided further data.

Studies were excluded if they: were not randomized, were primary prevention studies (ie. restricted to patients without documented CAD), evaluated single-modality interventions (such as exercise-only programs, yoga interventions, or telephone follow-up),

tested interventions delivered to hospitalized patients rather than outpatients, did not include a “usual care” arm, or tested interventions that were not provided by health professionals (such as letter reminders, self help groups, self-directed interventions, or general health promotion interventions). Studies in which patients with multiple diseases were enrolled were included if the outcomes for patients with coronary heart disease were reported separately or if that data was provided by the study principal investigator when contacted.

Two of the investigators (AC and FM) assigned each reported intervention independently to one of 3 *a priori* defined groups: (1) *Comprehensive Cardiac Rehabilitation* (programs which included exercise with group education and counseling sessions about coronary risk factor management), (2) *Group Cardiac Rehabilitation without exercise component* (programs which included group education and counseling sessions about coronary risk factor management, but no structured exercise component), or (3) *Individual Counseling* (programs, usually delivered by specially trained nurses, involving individual education and counseling sessions and individual follow-up, either in person or by telephone, to

encourage coronary risk factor optimization). Patient education was a key component of all 3 types of interventions (see Tables 1 and 5 for a more detailed description of the program in each included trial). Data on the methodological quality of the trials were also independently extracted and verified.

Statistical analyses:

Analyses were performed using RevMan 4.2 (The Cochrane Collaboration 2004). Our primary outcome was all-cause mortality. Secondary outcomes that were meta-analyzed were recurrent myocardial infarctions and hospitalizations. We attempted to obtain data on all-cause hospitalizations wherever possible; however for some trials, even after contact with the primary study authors, we could only obtain data on cardiovascular hospitalizations. We defined “hospitalization rate” as the number of patients in each trial arm who were hospitalized at least once (thus, each patient could only contribute one event to these analyses).

As the outcomes were relatively common, risk ratios were calculated and the I^2 statistic was used to assess for heterogeneity in each outcome of interest. Studies were combined using the DerSimonian and Laird random effects model. Analyses were

conducted for each of the three types of programs: comprehensive cardiac rehabilitation, cardiac rehabilitation (without exercise component), and individual counseling. For the primary analysis, we used data from the longest follow-up period reported in each trial. We also conducted analyses using the various follow-up periods reported (6, 12, 24, 36, 48, 56, 60, and 72 months).

Due to a lack of consistency in how they were measured and/or reported (ie. different trials used different scales or measurements and while some trials reported mean/median results for continuous variables others transformed these same variables into binary variables for analyses and reporting), we described, but did not meta-analyze, the following outcomes: effects on major cardiovascular risk factors (cholesterol, smoking, blood pressure), use of proven efficacious therapies, patient quality of life, and patient functional status or symptom scores. These were evaluated and categorized as: statistically significant benefit seen in the intervention arm versus the control arm; trend towards better outcomes in the intervention arm which did not reach statistical significance; or, no appreciable difference between the intervention and control arms. In order to standardize the reporting of results for non-dichotomous outcomes

(such as change in cholesterol or blood pressure levels, quality of life, or functional status scores), we calculated standardized effect sizes by dividing the absolute difference between intervention and control arms by the standard deviation in the control arms. By convention, effect sizes <0.20 are considered trivially small, 0.50 moderate, and >0.80 large.

Exploring the impact of program components on clinical outcomes: A meta-regression

The effectiveness of an intervention is not just a consequence of a small number of macro characteristics, such as program type. Other program characteristics and the context in which the intervention is introduced are also likely to influence its provision and possibly its effectiveness [26].

A meta-regression was therefore undertaken to identify the association of several components of programs (see Tables 5a,b,c) with our main outcomes: all-cause mortality, recurrent myocardial infarctions, and all-cause hospitalizations.

To provide more details regarding program characteristics and given the paucity of details in published reports, in order to conduct the meta-regression we had to contact primary study authors for

further data on program characteristics (see Appendix C for the standardized email survey items sent to the primary study authors, Figure 10 for outline of survey steps, and Appendix D for summary of missing data before/after the survey). All 46 trials were screened by 2 investigators independently to extract the characteristics outlined in Appendix C. Further details were required for 34 of the trials- we could not trace 3 of the primary study authors (even using Google searches). Overall response rate to the survey was 87% (27/31), resulting in 36 additional variables being identified.

Since we had a larger number of studies than most meta-analyses, we decided to do a forward step-wise multiple meta-regression rather than the univariate meta-regression that one is often restricted to with smaller numbers of studies. The following covariates were considered in the regression: location of study intervention (i.e. hospital, community, etc.), time to commencement after index event, mean length of study, number of intervention sessions, degree of individualization, presence of prescribing nurse or pharmacist, type of physician involvement, supplementary telephone support, and theoretical basis for treatment (i.e. stage of change, cognitive, etc.). As there have been no previous meta-

regressions of secondary prevention programs, these co-variables were selected based on: the factors identified as being potentially salient during the Medicare Coverage Advisory Committee Meeting, the terms used in the Medicare Coverage Advisory Committee evaluative questions, the common dimensions along which secondary preventions programs tend to differ, and what data on programs would realistically be available. Due to the expected large disparity in values for continuous variables, the variables *time to commencement after index event* and *number of sessions* were analyzed on the logarithmic scale.

RESULTS

Study selection and evaluation:

Overall we identified 6,345 citations from electronic databases (n=6,207), reference lists (n=45), and the Centers for Medicare and Medicaid Services (n=93). We reviewed 254 full manuscripts for potential inclusion. We excluded 196 of these studies after detailed evaluation; the reasons for exclusion are detailed in Figure 1 and Appendix A (a full list of excluded studies is included in Appendix B).

Disagreement among the reviewers regarding eligibility of the studies occurred on 16 occasions for a kappa value of 0.81. All disagreements were resolved by consensus.

Of the randomized trials eligible for inclusion,[28-85] 9 were reported in more than one publication. Two trials reported different endpoints in two separate publications.[28,29,57,58] One trial[30] reported the outcomes for all patients enrolled (only 56% of whom had cardiac disease) and, in a separate publication[31], provided details of event rates in the subgroup of patients with cardiac disease. The WHO Trial[32] included 24 collaborating centers; however, the original investigators excluded 7 sites because of poor

subject follow-up, and 4 sites due to significant differences at baseline between the intervention and control arms. We included the 3-year outcome data from the remaining 13 sites as one trial for the purposes of this analysis, an approach validated by the non-significant tests for statistical heterogeneity for all-cause mortality ($Q=15.7$, 11 df, $p=0.16$) and MI ($Q=15.9$, 11 df, $p=0.15$) and the fact that the summary risk ratios for both endpoints were identical under the random and fixed effects models. While the two Finnish centers in the WHO Trial published their results separately (and for multiple follow-up periods), we included only their 3-year outcome data with the other 11 WHO sites for consistency of data presentation.[33-35] In five cases, we identified studies that reported longer follow-up data from another relevant trial.[36-40]

Studies included in the systematic review:

Summary data from the 46 unique randomized trials eligible for this systematic review are presented in Table 1.[28-85] In all of the trials, patients randomized to the control groups received usual care (which was generally undefined). One trial [41] is presented twice in Table 1 because it had two intervention groups (comprehensive cardiac rehabilitation and group counseling) as well as a usual care

control arm. Although all of the control patients were included for the subgroup analyses in which this trial was relevant (comprehensive cardiac rehabilitation versus usual care, and group cardiac rehabilitations versus usual care), for the overall analyses (in which all 3 types of secondary prevention programs in the 46 trials were pooled, we only included the control arm patients once).

Our search retrieved 34 trials not included in our previous systematic review (that was limited to the pre-1999 literature)[25] and 26 trials not included in a more recent systematic review of cardiac rehabilitation (that was based on an earlier Cochrane review and limited to the pre-2003 literature on exercise interventions)[22,23].

Quantitative data synthesis:

All-cause mortality: Only one of the 29 trials reporting this outcome found a statistically significant survival benefit with the intervention (Table 2, Figures 2-4). The summary RR for all 29 trials reporting all-cause mortality (13 857 patients) was 0.87 (95% CI 0.79-0.97), using the data from the entire follow-up period in each trial (which ranged from 6 months to 6 years), with no significant statistical heterogeneity between trials ($p=0.95$, I-squared=0%). Pooling the data at the 12 month follow-up visit in each trial (or as close to 12

months as possible), the summary RR for all 29 trials was 0.90 (95% CI 0.79-1.01), with no significant statistical heterogeneity between trials ($p=0.90$, I-squared=0%).

Although there was no appreciable difference in the treatment effects with any of the 3 types of secondary prevention programs (Table 2, Figures 2-4), there were differences in effect over time. While the RR for all-cause mortality was 0.97 (95% CI 0.82-1.14) in the 19 trials (9393 patients, p for heterogeneity=0.95, I-squared=0%) reporting 12 month outcome data, the RR for all-cause mortality was 0.53 (95% CI 0.31-0.92) in the 4 trials (1367 patients, p for heterogeneity=0.44, I-squared=0%)[40,41,43,77] reporting 24 month outcome data. Furthermore, pooling the data from the 5 trials (2273 patients)[28,39,40,42,71,72] reporting follow-up data from at least 5 years after initiation of the intervention program demonstrates that programs had a sustained beneficial effect: the RR for all-cause mortality was 0.76 (95% CI 0.62-0.92) at 5 years with no appreciable heterogeneity between the trials ($p=0.93$, I-squared=0%).

Re-infarction Rate: One of the 17 trials reporting this endpoint (Table 2, Figures 5-7) detected a significant difference between intervention and control patients and the summary RR for

re-infarction rate at longest follow up for all 9526 patients was 0.83 (95% CI 0.72-0.96) with no significant heterogeneity ($p=0.39$, $I^2=6\%$). At 12 months, or as close as possible to 12 months, (17 trials, $n=9258$), the RR of re-infarction was 0.80 (95% CI 0.65-0.99) in patients randomized to secondary prevention programs. There was no significant statistical heterogeneity among trials at 12 months ($p=0.24$, $I^2=18\%$). There was no appreciable difference in the treatment effects with any of the 3 types of secondary prevention programs (Table 2, Figures 5-7), neither were there any differences in effect over time.

Hospitalization Rate: Two of the 13 trials (5751 patients) reporting hospitalization rates detected a significant difference between intervention and control patients. The summary random effects RR for hospitalization rates for all 5751 patients was 0.85 (95% CI 0.78-0.93)- (Figure 8). There was no significant statistical heterogeneity between trials ($p=0.24$, $I^2=20\%$) despite the fact that some trials reported data on all-cause hospitalizations and some on only cardiovascular hospitalizations. Median length of follow-up in these trials was approximately 12 months.

Restricting our analysis to the 9 trials (3653 patients) which reported all-cause hospitalization rates revealed a summary random effects RR of 0.84 (95% CI 0.74-0.97). Restricting our analysis to the 7 trials (3233 patients) which reported cardiovascular hospitalization rates revealed a summary random effects RR of 0.76 (95% CI 0.58-0.98).

Sensitivity Analyses: Analyses failed to reveal any effect of publication year on the observed results (data not shown).

Publication Bias: There was no evidence of publication bias (see Funnel Plot in Figure 9 for our primary outcome of all-cause mortality). The results of Begg's Test ($p=0.41$) and Egger's Test ($p=0.88$) confirm this.

Processes of Care: Twenty-seven trials tested the impact of these disease management programs on cardiovascular risk factors. Twenty two demonstrated better cholesterol profiles in patients randomized to the interventions, although the differences were statistically significant in only 14 trials and the effect sizes were generally small to moderate (Table 3). Of the 20 trials that assessed the use of proven efficacious medications, 8 demonstrated statistically significantly better application of at least one of these

therapies in the intervention patients, 2 demonstrated better prescribing in intervention patients but did not achieve statistical significance, and 10 failed to demonstrate any appreciable difference between intervention and control patients (Table 3). It should be noted that in many cases the failure to demonstrate improved processes of care with the intervention was because of improved risk factor management in control patients. For example, in one study that followed patients for over 4 years, 55% of controls had been exposed to comprehensive secondary prevention clinics by the close of the study.[37]

Other Endpoints: Eighteen of the 30 trials evaluating quality of life or functional status reported statistically significantly better scores in those patients exposed to the intervention programs, although the effect sizes were generally small (Table 3). Only 7 of these trials[30,44,49,50,65,66,105] described the costs of the intervention- while 2[30,50] reported that their intervention was cost-saving, only 1 performed formal cost-effectiveness analyses (and demonstrated an incremental cost per quality-adjusted life year of £1097). Another trial did not report costs, but did report that patients in the intervention arm had fewer visits to physicians as outpatients,

fewer emergency room visits, less laboratory testing, and fewer total hospital days in follow-up than control patients.[83] Another trial reported statistically significantly lower inpatient bed days in intervention arm patients over 4 years of follow-up compared to controls (Dr. M. Vale, personal communication, January 10 2005).[81]

Methodologic Quality:

None of these trials were double-blind (not surprising considering the nature of the intervention) and very few described randomization procedures or accounted for discrepancies between recruitment and follow up sample sizes. As a result, Jadad quality scores were clustered around 2 (Table 4). None of the trials reported side effects with the secondary prevention programs beyond the adverse clinical outcomes described below.

Exploring the impact of program components:

Program Descriptions (Table 5a,b,c and Appendix E):

Physicians adopted a coordinating role in only 4 programs (9%); conversely, 8 programs (17%) had no physician involvement. In the majority of interventions (52%) physicians only supervised exercise stress tests or exercise sessions. Most programs (78%) utilized professionals who were either specialists in cardiac

rehabilitation or in the cardiac area. Only 15% of these programs reported being based on one or more theory of behavioral change; these included social cognitive, learning, and motivational theories. Only one quarter of the interventions were based on stated guidelines. The relatively recent emergence of guidelines for cardiac prevention and rehabilitation may account for this small proportion.

Around one third of interventions were standardized in terms of components and content. Hence, all patients received a virtually identical program. The greatest proportion of programs (43%) had the level of individualization that would be expected with usual care, i.e. with inclusion and intensity of a limited range of prescribed exercise regimes based on exercise stress test results or, with counseling interventions, programs involving direct interactions with health professionals but little formalized or detailed patient assessment. However, 23% reported individualizing the components patients received and/or the content of these components based on assessments substantially more involved than is typical for usual care. This heightened level of individualization reflected significant and formalized individual assessment of needs, goals and preferences, and alteration thereon of program components offered

and/or the specific content of a component. Five programs individualized both the components offered to patients and the contents of interventions within each component. The vast majority of programs (87%) did not include pharmacist or nurse prescribing of medications. Only 39% of these interventions incorporated telephone support of patients.

Meta-Regression: None of the program components described in Table 5 demonstrated a significant effect on all-cause mortality or on recurrent myocardial infarctions. While the lack of a significant effect for particular program components may be seen as a disappointing result, the converse is important to emphasize: namely, shorter programs and programs delivered by non-specialists were just as effective as longer programs and programs delivered by specialists (Figures 11 and 12 respectively). For example, programs containing 10 hours or less of direct or telephone-based contact between patients and health professionals were effective at reducing all-cause mortality (RR 0.80, 95% CI 0.68 to 0.95, n=4307 in 9 trials) and were at least as effective as longer programs (Figure 11). Further, interventions that were based in non-hospital settings were effective in reducing all-cause mortality (RR 0.76 95% CI 0.63 to

0.92; n=2628 in 3 trials) and compared well with hospital-based programs (RR 0.90, 95% CI 0.79 to 1.03, n=9057 in 21 trials).

For hospitalizations, programs with increased degrees of individualization had greater impacts ($p < 0.001$ in the meta-regression, RR 0.74, 95% CI 0.65 to 0.85, for those programs classified as having individualized components consistent with, or greater than, usual care), as did programs with nurse prescribing ($p = 0.007$), although it should be noted in the latter case that there was only one study (of those reporting on all-cause hospitalizations) that had a prescribing nurse- see Figures 13 and 14.

DISCUSSION

In summary, the weight of the published randomized trial evidence suggests that comprehensive secondary prevention programs positively impact on processes of care (risk factor profiles, use of proven efficacious therapies) which are closely linked to subsequent morbidity and mortality in patients with CAD.[86] Pooling the data from those trials which reported subsequent rates of MI reveals a statistically significant 17% relative risk reduction in recurrent MIs over a median follow-up of 12 months. The majority of these programs also demonstrate improved symptom scores, exercise tolerance, or quality of life in participants. The mortality benefit derived from participation in the secondary prevention programs we identified became apparent with longer follow-up (47% at 2 years and 24% at 5 years). This is not surprising given that the natural history of atherosclerotic CAD dictates that changes in coronary risk factors would not be expected to produce immediate improvements in atherosclerotic plaque stability or coronary artery diameter. There was a statistically significant 15% relative risk reduction in hospitalizations (driven by a statistically significant 24% reduction in cardiovascular hospitalizations) over a median follow-up

of 12 months. These early beneficial effects on hospitalizations mirror the findings of a recent systematic review of multidisciplinary strategies for patients with heart failure which found that such interventions reduce hospitalizations by 25% within 6 months of implementation.[87]

Some comprehensive lifestyle modification programs under consideration by the Medicare Coverage Advisory Committee were not included in our analysis as they had not been evaluated in randomized controlled trials. However, our analyses extend the evidence base from these other programs to show significant benefits on hard clinical endpoints. Though none of the papers included were replication studies (i.e. tested interventions found to be effective previously in different settings), subsequent studies have confirmed that the Ornish multi-component cardiac rehabilitation program [71] can be successfully taught and implemented at various sites in the United States [88] and should be cost-saving.[89] However, while this economic analysis suggests that cost reductions in the order of 30% to 60% for care within the first year are possible, the analyses are based on observational data (two concurrent cohorts followed for one year in one study, matched claims data analyses in another

study, and two studies comparing actual costs after participation in the Ornish Program versus predicted costs) rather than randomized trial evidence.[89] A recent analysis of direct health care costs at 30 cardiac rehabilitation centres in the United Kingdom's NHS for the fiscal year 2000-2001 reported an average cost of £486 per patient who completed a cardiac rehabilitation program (with most of the cost, or £354 per patient, being attributed to staff salary costs).[90] However, citing an average cost is misleading since program costs varied widely across centres (depending on duration of interventions and staff to patient ratios amongst other factors) and the investigators demonstrated that economies of scale could be achieved in that costs were projected to fall by 0.25% per patient for every 1% increase in patient throughput. Although very few of the trials we identified for this review reported costs, the reality is that the 1-2 year follow up period of many of these trials is too short anyway to fully evaluate the cost-effectiveness of secondary prevention programs and while studies with 5 and 10 year time horizons are ongoing, more studies that include long term measurement of outcomes and costs are needed.

Previously published systematic reviews of cardiac rehabilitation in survivors of myocardial infarction have reported survival benefits in the order of 20-24%. However, most of the trials included in those overviews evaluated single modality exercise-based interventions and thus were not included in our overview. For example, a recently published meta-analysis reported a statistically significant 20% reduction in all-cause mortality in 8432 patients; however, closer inspection of this report reveals that 40% of the data in the mortality analysis came from 13 trials that evaluated exercise-only programs and from 2 trials which were excluded from our systematic review because of lack of a usual care control arm.[23]

Activity levels are inversely proportional to cardiovascular mortality and exercise training confers substantial physiologic and clinical benefits (including changes in endothelial function, autonomic tone, inflammatory markers)[24,91]. It is thus not surprising that trials comparing exercise training to no exercise found greater treatment effects than the trials included in our review which evaluated secondary prevention programs that were not primarily exercise-based. However, the selection of programs included in our review was driven by current guideline recommendations and the request of

the Medicare Coverage Advisory Committee that secondary prevention programs should not include comparisons of supervised exercise programs versus no exercise (a control arm that is no longer “usual care”).[18,26] Our systematic review demonstrates that a wide variety of secondary prevention programs delivered by health care providers, in addition to having beneficial effects on patient risk factor profiles and quality of life/functional status, provide tangible reductions in clinically relevant endpoints such as hospitalization and death.

As a corollary to this review and in recognition of the interest of some in defining the impact of exercise-only programs, we conducted a systematic review of 17 trials (2566 patients) comparing supervised exercise training programs with no exercise and incorporated this data into a meta-comparison of exercise-based rehabilitation programs versus programs which did not incorporate an exercise training component.[92] While we demonstrated that supervised exercise training reduced mortality by 28% (95% CI 5% to 46%) compared to controls who did not receive exercise training, this degree of benefit was not statistically significantly different from the benefits seen with secondary prevention programs that did not

incorporate a structured exercise component (mortality reduction 13%, 95% CI 1% to 24%).

Why didn't the trials reporting 12 month outcome data (including over 9000 subjects) demonstrate a statistically significant survival benefit? First, 12 months was clearly too short to show a marked impact on mortality- this conclusion is not only supported by knowledge of the pathophysiology of atherosclerotic CAD but also by data demonstrating a significant survival benefit in those studies reporting outcomes over 2 years or more. It should be emphasized that studies which did evaluate coronary angiographic lesions at baseline and after 12 months did report statistically significant regression rates in patients compliant with comprehensive lifestyle modifications within 12 months even without significant changes in metabolic profiles or medication usage.[39,71] Second, the patients included in these studies were at sufficiently low risk over the first year after enrollment that the likelihood of detecting a beneficial effect was remote- indeed, the control event rates in these trials were substantially lower than those in other trials enrolling patients with clinically overt CAD. Third, the incremental benefit of secondary prevention programs over usual care may be very small in the

settings in which the trials were carried out (where management in the “usual care” arm may be atypically close to optimal already). Indeed, secondary prevention programs are likely to be most beneficial in those settings where usual care is sub-optimal. Finally, it is possible that the labeling of patients with one disease for special attention in a disease-specific management program may have led to sub-optimal care for their co-morbid conditions and, as a result, no real difference in all-cause mortality.[93]

The overall effectiveness of secondary prevention programs should also be interpreted in the context of the unexplained inconsistencies in effectiveness between different types of programs. We attempted to ‘open the black box’ to identify what the key characteristics of successful programs were, which components were most influential, or how particular program or setting characteristics influenced patients and health outcomes. However, although we obtained detailed data from the vast majority of primary study authors, our meta-regression did not find any factors which significantly drove the results for all-cause mortality or recurrent MIs. The particular mechanisms of effect of interventions remain poorly understood. Translation of the theoretical benefits of secondary

prevention programs into real-world patient benefit is also dependent on suitable patients being referred to, accessing, and completing the programs. Health outcomes research has consistently demonstrated that even in publicly funded health care systems where access is free, only a minority of patients (less than one quarter to one half) ultimately access these programs.[10,90,94] Moreover, those groups that are less likely to be referred, to attend, and to complete programs are often those in greatest need of additional support and risk reduction, such as women, the elderly, low income groups, and ethnic minorities.[90] These groups were underrepresented in the studies reviewed.

Generalizability of the trial data:

The trials included in this review enrolled relatively young patients- some even excluded patients over the age of 65 (see Tables 1 and 6). This raises potential concerns about the generalizability of our findings to this increasingly large segment of the population that is especially vulnerable to CAD. However, there is evidence that elderly patients derive similar benefits from secondary prevention programs as younger patients.[95-98] While it is now less common for programs to have age-based restrictions for

entry, older adults are frequently excluded from programs due to a lack of program capacity to address their complex health needs or limited resources.[99,100] The effectiveness of programs for older patients may therefore be dependent not only on program content but also on program capacity to provide effective care to patients who have multiple co-morbidities.

Women were also underrepresented in the studies reviewed (Table 7) and data were not available to examine results by gender. This imbalance is significant because although CAD remains the leading cause of death for women in most of the developed world [101], it is often erroneously viewed as principally being a “disease of men”. Gender differences in the investigation and management of CAD have been evident for many years.[102] Consequently, the need for improved and more responsive management of CAD in women has now been recognized by international guidelines.[102] While there is no evidence of any gender-based barriers to program benefit, women are consistently identified as being less likely to access programs.[94,103] To increase the strength of evidence supporting the benefits of programs to women, more women should

be included in studies, and studies should examine the effectiveness of programs in males versus females.

Finally, as with any intervention that is efficacious in trial settings, the applicability of this evidence to the “real-world setting”, where compliance is likely to be highly variable and generally lower than that observed in trial participants, is a potential concern. This may lead some to conclude that the results we report should be viewed as a “best case scenario” for the impact of secondary prevention programs. However, this view neglects the fact that randomized trial participants assigned to the control arm often also receive care which is better than typical usual care. Indeed, as we pointed out earlier, the incremental benefit of secondary prevention programs over usual care may be very small in the settings in which these trials were carried out, where management in the “usual care” arm was often close to optimal already. Indeed, it is likely that secondary prevention programs will be more beneficial in other settings that are more akin to the “real world” of current clinical practice where usual care is sub-optimal.

Limitations of this Review:

As with all systematic reviews, this study has a number of potential limitations. The most obvious arise from the primary data (lack of blinding in outcome ascertainment, lack of detail on whether randomization was conducted properly or whether allocation concealment was achieved, and our inability to identify unpublished studies- although we did not find any evidence for publication bias) and, as all tend to result in over-estimation of any treatment effects,[104] these factors should be taken into account when interpreting our summary estimates. Our interpretation of these trials and the generalizability of the programs are hampered by our inability, even with additional unpublished data from 87% of the trials and the use of meta-regression, to determine the incremental benefits of the various components of each intervention. Determining the optimal mix of interventions, including their frequency and duration, should be a priority for future research studies in this field. While some may criticize our choice of primary endpoints as being too broad to detect differences in “cardiac” morbidity and mortality, we believe that it is most appropriate to look at all-cause mortality or hospitalization as interventions to reduce resource use in one area

can have unanticipated effects in another. Finally, we are unable to make a definitive comment on the cost-effectiveness and economic impact of the programs tested in these trials due to the paucity of relevant data and the likelihood that costs for program delivery will vary widely between different areas and different types of programs (depending on duration of the programs and staff-patient ratios in particular).

CONCLUSION

In summary, although there was substantial variability in the interventions offered and the studies enrolled highly selected populations, secondary prevention programs do improve processes of care, coronary risk factor profiles, and functional status/quality of life. Though the optimal mix of interventions, including their frequency and duration, are unclear, these programs do reduce hospitalizations, subsequent myocardial infarctions, and mortality in patients with known CAD. While these programs appear to reduce health care resource use, their cost-effectiveness has been inadequately evaluated thus far in the literature. Thus, we believe that any policy decisions to implement secondary prevention programs on a wide scale should be accompanied by plans to rigorously evaluate long-term clinical and economic outcomes in participants and non-participants.

ACKNOWLEDGEMENTS: The authors gratefully acknowledge the help of Dr. N.C. Campbell (references 28 and 29), Dr. R. West (reference 46), Dr. M. Naylor (references 30, 31, and 50), Dr. N. Marchionni (reference 66), Drs. Vale and Sundararajan (reference 81), Dr. Otterstad and Ms. Peersen (reference 82), Dr. W. Young (reference 83), Drs. K. Jolly and J. Bell (reference 85), Dr. J.K. Allen (reference 51), Dr. T.G. Allison (references 52, 53), Dr. M.E. Cupples (reference 40, 45), Drs. R.F. De Busk et al. (via Dr. Taylor, reference 44), Dr. H. Hamalainen (reference 35), Dr. W.L. Haskell (reference 43), Dr. H. Higgins (reference 60), Dr. M. Johnston (reference 61), Dr. S. Lear (reference 62), Dr. J.H. Lichtman (via Dr. Krumholz, reference 63), Dr. J. Lisspers. (reference 64), Dr. S. Masley. (reference 65), Dr. F. McHugh (via Dr. G Lindsay, reference 67), Drs. P. Murchie and N Campbell (references 37 and 38), Dr. D. Ornish (references 70, 71, and 72), Dr. M. Stagmo. (reference 76), Dr. O. Sundin (via Dr. Lisspers, reference 78), and Dr. Toobert (reference 79) for providing further details about their studies and/or interventions.

The authors also thank the staff of the University of Alberta Evidence-based Practice Center who participated in generating this report:

Carol Friesen (searching), John Russell (retrieving articles, administrative tasks), Marilyn Josefsson (retrieving articles, administrative tasks), Natasha Wiebe (screening), Michelle Tubman (screening), Kenneth Bond (kappa calculations).

The authors also thank those who assisted in undertaking the survey of primary study authors: Sue Lissel (screening, survey data extraction and collation of results), Jessica McNeill (identification of author contact information), Stephanie Heath, and Nicole Freyberg (presentation of results).

REFERENCES

1. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999. The Framingham Heart Study. *Circulation* 2004;110:522-7.
2. American Heart Association. Heart Disease and Stroke Statistics — 2005 Update. Dallas, Tex.: American Heart Association; 2004
3. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases, part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. *Circulation* 2001;104:2746-53.
4. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 2004;364:937-52.
5. Majumdar SR, Tsuyuki RT, McAlister FA. Controlling the ischemic heart disease epidemic: strategies for the 21st century. *Can J Public Health* 2001;92:9-11.
6. Yusuf S. Two decades of progress in preventing vascular disease. *Lancet* 2002;360:2-3.
7. Majumdar SR, McAlister FA, Furberg CD. From publication to practice in chronic cardiovascular disease – The Long and Winding Road. *J Am Coll Cardiol* 2004;43:1738-42.

8. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. *Lancet* 2001;357:995-1001.
9. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. *J Am Coll Cardiol* 2003;41:56-61.
10. Witt BJ, Jacobsen SJ, Weston SA, Killian JM, Meverden RA, Allison TG, et al. Cardiac rehabilitation after myocardial infarction in the community. *J Am Coll Cardiol* 2004;44:988-96.
11. McCormick D, Gurwitz JH, Lessard D, Yarzebski J, Gore JM, Goldberg RJ. Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention? *Arch Intern Med.* 1999;159:561-67.
12. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. *J Gen Intern Med.* 1999;14:711-17.
13. Campbell NC, Thain J, Dean HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. *BMJ* 1998;316:1430-4.
14. Brady AJB, Oliver MA, Pittard JB. Secondary prevention in 24 431 patients with coronary heart disease: survey in primary care. *BMJ* 2001;322:1463.

15. Califf RM, DeLong ER, Ostbye T, et al. Underuse of aspirin in a referral population with documented coronary artery disease. *Am J Cardiol* 2002;89:653-61.
16. World Health Organisation. *Adherence to long-term therapies: evidence for action*. Geneva: WHO, 2003.
17. Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. *JAMA* 2002;288:455-61.
18. Balady GJ, Ades PA, Comoss P, Limacher M, Pina IL, Southard D, et al. Core components of cardiac rehabilitation / secondary prevention programs. *Circulation* 2000;102:1069-1073.
19. O'Connor GT, Buring JE, Yusuf S, Goldhaber SZ, Olmstead EM, Paffenbarger RS, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. *Circulation* 1989;80:234-44.
20. Oldridge NB, Guyatt GH, Fischer ME, Rimm AA. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. *JAMA* 1988;260:945-50.
21. Dinnes J, Kleijnen J, Leitner M, Thompson D. Cardiac rehabilitation. *Qual Health Care* 1999;8:65-71.
22. Jolliffe JA, Rees K, Taylor RS, Thompson D, Oldridge N, Ebrahim S. Exercise-based rehabilitation for coronary heart disease. *The Cochrane Database of Systematic Reviews* 2001, Issue 1. Art. No.: CD001800. DOI: 10.1002/14651858.CD001800

23. Taylor RS, Brown A, Ebrahim S, Jolliffe J, Noorani H, Rees K, et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. *Am J Med* 2004;116:682-92.
24. Shephard RJ, Balady GJ. Exercise as cardiovascular therapy. *Circulation* 1999;99:963-72.
25. McAlister FA, Lawson FME, Teo KK, Armstrong PW. Randomised trials of secondary prevention programs in coronary heart disease: systematic review. *BMJ* 2001;323:957-62.
26. Pawson R. Evidence-based policy: The promise of 'realist synthesis'. *Evaluation* 2002;8(3):340-358.
27. Phillips CO, Singa RM, Rubin HR, Jaarsma T Complexity of program and clinical outcomes of heart failure disease management incorporating specialist nurse-led heart failure clinics: A meta-regression analysis. *European Journal of Heart Failure* 7: 333-341.
28. Campbell NC, Thain J, Deans HG, Ritchie LD, Rawles JG, Squair JL. Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. *BMJ* 1998;316:1434-7.
29. Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JG, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. *Heart* 1998;80:447-52.

30. Naylor MD, Brooten D, Campbell R, Jacobsen BS, Mezey MD, Pauly MV, et al. Comprehensive discharge planning and home follow-up of hospitalized elders. A randomized clinical trial. *JAMA* 1999;281:613-20.
31. Naylor MD, McCauley KM. The effects of a discharge planning and home follow-up intervention on elders hospitalized with common medical and surgical cardiac conditions. *J Cardiovasc Nurs* 1999;14:44-54.
32. World Health Organization Report 84: Rehabilitation and comprehensive secondary prevention after acute myocardial infarction. Copenhagen;1983:1-99.
33. Kallio V, Hamalainen H, Hakkila J, Luurila OJ. Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. *Lancet* 1979;ii:1091-4.
34. Hamalainen H, Luurila OJ, Kallio V, Knuts L-R, Arstila M, Hakkila J. Long-term reduction in sudden deaths after a multifactorial intervention programme in patients with myocardial infarction: 10-year results of a controlled investigation. *Eur Heart J* 1989;10:55-62.
35. Hamalainen H, Luurila OJ, Kallio V, Knuts L-R. Reduction in sudden deaths and coronary mortality in myocardial infarction patients after rehabilitation. *Eur Heart J* 1995;16:1839-44.
36. Taylor CB, Miller NH, Smith PM, DeBusk RF. The effect of a home-based, case-managed, multifactorial risk-reduction program on reducing psychological distress in patients with cardiovascular disease. *Journal of Cardiopulmonary Rehabilitation* 1997;17:157-62.

37. Murchie P, Campbell NC, Ritchie LD, Simpson JA, Thain J. Secondary prevention clinics for coronary heart disease: four year follow up of a randomised controlled trial in primary care. *BMJ* 2003;326:84.
38. Murchie P, Campbell NC, Ritchie LD, Deans HG, Thain J. Effects of secondary prevention clinics on health status in patients with coronary heart disease: 4 year follow-up of a randomized trial in primary care. *Family Practice* 2004;21(5):567-74.
39. Niebauer J, Hambrecht R, Velich T, Hauer K, Marburger C, Kaulberer B, et al. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention. *Circulation* 1997;96:2534-41.
40. Cupples ME, McKnight A. Five year follow up of patients at high cardiovascular risk who took part in randomised controlled trial of health promotion. *BMJ* 1999;319:687-8.
41. P.RE.COR. Group. Comparison of a rehabilitation programme, a counselling programme and usual care after an acute myocardial infarction: results of a long-term randomized trial. *European Heart Journal* 1991;12:612-6.
42. Vermeulen A, Lie KI, Durrer D. Effects of cardiac rehabilitation after myocardial infarction: Changes in coronary risk factors and long-term prognosis. *Am Heart J* 1983;105:798-801.
43. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko R, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with

- coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). *Circulation* 1994;89:975-90.
44. DeBusk RF, Houston Miller N, Superko R, Dennis CA, Thomas RJ, Lew HT, et al. A case-management system for coronary risk factor modification after acute myocardial infarction. *Ann Intern Med* 1994;120:721-9.
 45. Cupples ME, McKnight A. Randomised controlled trial of health promotion in general practice for patient at high cardiovascular risk. *BMJ* 1994;309:993-6.
 46. Jones DA, West RR. Psychological rehabilitation after myocardial infarction: multicentre randomized controlled trial. *BMJ* 1996;313:1517-21.
 47. Frasure-Smith N, Lesperance F, Prince RH, Verrier P, Garber RA, Juneau M, et al. Randomised trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction. *Lancet* 1997;350:473-9.
 48. Jolly K, Bradley F, Sharp S, Smith H, Thompson S, Kinmonth AL, et al for the SHIP Collaborative Group. Randomised controlled trial of follow up care in general practice of patients with myocardial infarction and angina: final results of the Southampton heart integrated care project (SHIP). *BMJ* 1999;318:706-11.

49. Fitzgerald JR, Smith DM, Martin DK, Freedman JA, Katz BP. A case manager intervention to reduce readmissions. *Arch Intern Med* 1994;154:1721-9.
50. Naylor M, Brooten D, Jones R, Lavizzo-Mourey R, Mezey M, Pauly M. Comprehensive discharge planning for the hospitalized elderly. *Ann Intern Med* 1994;120:999-1006.
51. Allen JK, Blumenthal RS, Margolis S, Young DR, Miller ER III, Kelly K. Nurse case management of hypercholesterolemia in patients with coronary heart disease: results of a randomized clinical trial. *American Heart Journal* 2002;144:678-86.
52. Allison TG, Farkouh ME, Smars PA, Evans RW, Squires RW, Gabriel SE, et al. Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (A chest pain evaluation in the emergency room (CHEER) substudy). *American Journal of Cardiology* 2000;86:133-8.
53. Allison TG, Squires RW, Johnson BD, Gau GT. Achieving national cholesterol education program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. *Mayo Clinic Proceedings* 1999;74:466-73.
54. Bengtsson K. Rehabilitation after myocardial infarction. A controlled study. *Scandinavian Journal of Rehabilitation Medicine* 1983;15:1-9.
55. Carlsson R. Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary artery disease. Experiences from a hospital-

- based secondary prevention programme. *Scandinavian Cardiovascular Journal Supplement* 1998;50:1-20.
56. Carlsson R, Lindberg G, Westin L, Israelsson B. Influence of coronary nursing management follow up on lifestyle after acute myocardial infarction. *Heart* 1997;77:256-9.
57. Engblom E, Ronnema T, Hamalainen H, Kallio V, Vanttinen E, Knuts L-R. Coronary heart disease risk factors before and after bypass surgery: results of a controlled trial on multifactorial rehabilitation. *European Heart Journal* 1992;13:232-7.
58. Engblom E, Korpilahti K, Hamalainen H, Ronnema T, Puukka P. Quality of life and return to work 5 years after coronary artery bypass surgery. Long-term results of cardiac rehabilitation. *J Cardiopulm Rehabil* 1997;17:29-36.
59. Fridlund B, Hogstedt B, Lidell E, Larsson PA. Recovery after myocardial infarction. Effects of a caring rehabilitation programme. *Scandinavian Journal of Caring Science* 1991;5(1):23-32.
60. Higgins HC, Hayes RL, McKenna KT. Rehabilitation outcomes following percutaneous coronary interventions (PCI). *Patient Education and Counseling* 2001;43:219-30.
61. Johnston M, Foulkes J, Johnston DW, Pollard B, Gudmundsdottir H. Impact on patients and partners of inpatient and extended cardiac counselling and rehabilitation: a controlled trial. *Psychosomatic Medicine* 1999;61:225-33.

62. Lear SA, Ignaszewski A, Linden W, Brozic A, Kiess M, Spinelli JJ, et al. The extensive lifestyle management intervention (ELMI) following cardiac rehabilitation trial. *European Heart Journal* 2003;24:1920-7.
63. Lichtman JH, Amatruda J, Yaari S, Cheng S, Smith GL, Mattera JA, et al. Clinical trial of an educational intervention to achieve recommended cholesterol levels in patients with coronary artery disease. *American Heart Journal* 2004;147:522-8.
64. Lisspers J, Sundin O, Hofman-Bang C, Nordlander R, Nygren A, Ryden L, et al. Behavioral effects of a comprehensive, multifactorial program for lifestyle change after percutaneous transluminal coronary angioplasty: a prospective, randomized, controlled study. *Journal of Psychosomatic Research* 1999;46(2):143-54.
65. Masley S, Phillips S, Copeland JR. Group office visits change dietary habits of patients with coronary artery disease. The dietary intervention and evaluation trial (D.I.E.T.). *Journal of Family Practice* 2001;50(3):235-9.
66. Marchionni N, Fattirolli F, Fumagalli S, Oldridge N, Del Lungo F, Morosi L, et al. Improved exercise tolerance and quality of life with cardiac rehabilitation of older patients after myocardial infarction. Results of a randomized, controlled trial. *Circulation* 2003;107:2201-6.
67. McHugh F, Lindsay GM, Hanlon P, Hutton I, Brown MR, Morrison C, et al. Nurse led shared care for patients on the waiting list for coronary artery bypass surgery: a randomised controlled trial. *Heart* 2001;86:317-23.

68. Moher M, Yudkin P, Wright L, Turner R, Fuller A, Schofield T, et al for the Assessment of Implementation Strategies (ASSIST) Trial Collaborative Group. Cluster randomised controlled trial to compare three methods of promoting secondary prevention of coronary heart disease in primary care. *BMJ* 2001;322:1-7.
69. Oldridge N, Guyatt G, Jones N, Crowe J, Singer J, Feeny D, McKelvie R, et al. Effects on quality of life with comprehensive rehabilitation after acute myocardial infarction. *American Journal of Cardiology* 1991;67:1084-9.
70. Ornish D, Scherwitz LW, Doody RS, Kesten D, McLanahan SM, Brown SE, et al. Effects of stress management training and dietary changes in treating ischemic heart disease. *JAMA* 1983 Jan 7;249(1):54-9.
71. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* 1990 Jul 21;336(8708):129-33.
72. Ornish D, Scherwitz LW, Billings JH, Brown SE, Gould KL, Merritt TA, et al. Intensive lifestyle changes for reversal of coronary heart disease. *JAMA* 1998;280(23):2001-7.
73. Schuler G, Hambrecht R, Schlierf G, Niebauer J, Hauer K, Neumann J, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. *Circulation* 1992;86(1):1-11.
74. Seki E, Watanabe Y, Sunayama S, Iwama Y, Shimada K, Kawakami K, Sato M, Sato H, Mokuno H, Daida H. Effects of phase III cardiac

- rehabilitation programs on health-related quality of life in elderly patients with coronary artery disease: Juntendo Cardiac Rehabilitation Program (J-CARP). *Circ J* 2003;67(1):73-7.
75. Sivarajan ES, Bruce RA, Lindskog BD, Almes MJ, Belanger L, Green B. Treadmill test responses to an early exercise program after myocardial infarction: a randomized study. *Circulation* 1982;65(7):1420-8.
76. Stagmo M, Westin L, Carlsson R, Israelsson B. Long-term effects on cholesterol levels and the utilization of lipid-lowering drugs of a hospital-based programme for secondary prevention of coronary artery disease. *Journal of Cardiovascular Risk* 2001;8:243-8.
77. Stern MJ, Gorman PA, Kaslow L. The group counselling v exercise therapy study. A controlled intervention with subjects following myocardial infarction. *Archives of Internal Medicine* 1983;143:1719-25.
78. Sundin O, Lisspers J, Hofman-Bang C, Nygren A, Ryden L, Ohman A. Comparing multifactorial lifestyle interventions and stress management in coronary risk reduction. *International Journal of Behavioral Medicine* 2003;10(3):191-204.
79. Toobert DJ, Glasgow RE, Radcliffe JL. Physiologic and related behavioral outcomes from the Women's Lifestyle Heart Trial. *Ann Behav Med* 2000;22(1):1-9.
80. Vale MJ, Jelinek MV, Best JD, Santamaria JD. Coaching patients with coronary heart disease to achieve the target cholesterol: a method to bridge the gap between evidence-based medicine and the "real world" –

- randomized controlled trial. *Journal of Clinical Epidemiology* 2002;55:245-52.
81. Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL, et al. Coaching patients on achieving cardiovascular health (COACH). *Archives of Internal Medicine* 2003;163:2775-83.
82. The Vestfold Heartcare Study Group. Influence on lifestyle measures and five-year coronary risk by a comprehensive lifestyle intervention programme in patients with coronary heart disease. *European Journal of Cardiovascular Prevention and Rehabilitation* 2003;10:429-37.
83. Young W, Rewa G, Goodman SG, Jaglal SB, Cash L, Lefkowitz C, et al. Evaluation of a community-based inner-city disease management program for postmyocardial infarction patients: a randomized controlled trial. *CMAJ* 2003;169(9):905-10.
84. Yu C-M, Li LS-W, Ho HH, Lau C-P. Long-term changes in exercise capacity, quality of life, body anthropometry, and lipid profiles after a cardiac rehabilitation program in obese patients with coronary heart disease. *American Journal of Cardiology* 2003;91(1):321-5.
85. Bell JM. A comparison of a multi-disciplinary home based cardiac rehabilitation programme with comprehensive conventional rehabilitation in post-myocardial infarction patients.[PhD Thesis] London, United Kingdom: University of London; 1998.

86. Mant J, Hicks N. Detecting differences in quality of care: the sensitivity of measures of process and outcome in treating acute myocardial infarction. *BMJ* 1995;311:793-6.
87. McAlister FA, Stewart S, Ferrua S, McMurray JJV. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: A systematic review of randomized trials. *J Am Coll Cardiol* 2004;44:810-9.
88. Koertge J, Weidner G, Elliott-Eller M, Scherwitz L, Merritt-Worden TA, Marlin R, et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicentre Lifestyle Demonstration Project. *Am J Cardiol* 2003;91:1316-22.
89. DeVries A, Palmer A, Scheib C, Day B, Bennett S, Fetterolf D, Kantz T. Highmark Blue Cross Blue Shield. Medical Management Analysis: Financial Impact of the Dr. Dean Ornish Program for Reversing Heart Disease. February 14, 2002;4:3.
90. Beswick AD, Rees K, Griebisch I, Taylor FC, Burke M, West RR, Victory J, Brown J, Taylor RS, Ebrahim S. Provision, uptake and cost of cardiac rehabilitation programmes: improving services to under-represented groups. *NHS HTA Report Project Code 99/21/02*. 2004;8(41).
91. Hambrecht R, Wolff A, Gielen S, et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. *N Engl J Med* 2000;342:454-60.

92. Clark AM, Hartling L, Vandermeer B, McAlister FA. Randomized trials of secondary prevention programs in coronary heart disease: a systematic review. *Ann Intern Med* 2005;143:659-72.
93. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. *N Engl J Med* 1998;338:1516-20.
94. Thomas RJ, Miller NH, Lamendola C, Berra K, Hedback B, Durstine JL, et al. National survey of gender differences in cardiac rehabilitation programs. Patient characteristics and enrollment patterns. *Journal of Cardiopulmonary Rehabilitation* 1996;16(6):402-12.
95. Milani RV, Lavie CJ. Prevalence and effects of cardiac rehabilitation on depression in the elderly with coronary heart disease. *American Journal of Cardiology* 1998;81(10):1233-6.
96. Majeed FA, Cook DG. Age and sex differences in the management of ischaemic heart disease. *Public Health* 1996;110:7-12.
97. Lavie CJ, Milani RV. Cardiac rehabilitation and preventive cardiology in the elderly. *Cardiology Clinics*. 1999;17(1):233-42.
98. Ades PA, Waldmann ML, Gillespie C. A controlled trial of exercise training in older coronary patients. *Journal of Gerontology* 1995;50A:M7-11.
99. Clark AM, Sharp C, MacIntyre PD. The role of age in moderating access to cardiac rehabilitation in Scotland. *Ageing and Society* 2002;22:501-515.
100. Oldridge N. Cardiac rehabilitation in the elderly. *Aging (Milano)* 1998;10(4):273-83.

101. British Heart Foundation. Coronary Heart Disease Statistics. London: BHF, 2004.
102. Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women. *Circulation* 2004;109(5):672-693.
103. Cooper AF, Jackson G, Weinman J, Horne R. Factors associated with cardiac rehabilitation attendance: a systematic review of the literature. *Clinical Rehabilitation* 2002;16:541-552.
104. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. *JAMA* 1995;273:408-12.
105. Raftery JP, Yao GL, Murchie P, Campbell NC, Ritchie LD. Cost effectiveness of nurse led secondary prevention clinics for coronary heart disease in primary care: follow up of a randomized controlled trial. *BMJ* 2005;330:707.

Box 1: Modifiable coronary risk factors (adapted from reference 4)

Modifiable Risk Factor	Prevalence in cases with myocardial infarction	Population Attributable Risk (99% CI)	Odds Ratio (99% CI) adjusted for age, gender, and smoking
Smoking	65%	36% (34% to 39%)	2.3 (2.1-2.4)
Dyslipidemia	33%	54% (50% to 59%)	3.9 (3.4-4.4)
Diabetes Mellitus	18%	12% (11% to 14%)	3.1 (2.8-3.4)
Hypertension	39%	23% (22% to 25%)	2.5 (2.3-2.7)
Abdominal Obesity	46%	34% (30% to 37%)	2.2 (2.1-2.5)
Psychosocial Factors	-	29% (23% to 36%)	2.5 (2.2-2.9)
Daily consumption of fruits and vegetables	36%	13% (10% to 17%)	0.7 (0.6-0.8)
Regular physical activity	14%	26% (20% to 32%)	0.7 (0.7-0.8)
Regular alcohol consumption	24%	14% (9% to 20%)	0.8 (0.7-0.9)
All of the above combined	-	90% (88% to 92%)	129.2 (90.2-185.0)

In the INTERHEART Study, “dyslipidemia” was defined as ApoB/ApoA1 Ratio in top quintile vs. lowest quintile; “abdominal obesity” was defined as waist/hip ratio > 0.90 in men and >0.83 in women; “psychosocial factors” was defined as positive exposure to depression, perceived stress at work or home, moderate or severe financial stress, low locus of control, and/or major life events; “regular physical activity” was defined as moderate or strenuous exercise for at least 4 hours per week; “regular alcohol consumption” was defined as 3 or more times per week.

Table 1: Description of studies included

Study	Sample Size	Study Population (Location)	Mean Age	% Male	Key Components of Intervention	Duration of Intervention
Comprehensive Cardiac Rehabilitation (19 trials, 4208 patients)						
Sivarajan et al. (1982)	258 (170 in control and comprehensive secondary prevention arms)	Patients younger than 70 years discharged after AMI (USA)	57	>80%	Exercise program plus group education/counseling sessions about risk factor management	3 m
Vermeulen et al. (1983)	98	Males 40-55 yrs, discharged after AMI (Netherlands)	49	100%	Multidisciplinary team (details not given) involved in exercise rehabilitation, social and psychological supports for patients	1.5-2 m
Bengtsson (1983)	87	Patients aged <65 years, one year after AMI (Sweden)	56	85%	Rehabilitation program involving physical assessment and training by physiotherapy and counseling	3 m
World Health Organization* (1983)	1,735	Males < 65 yrs, discharged after AMI (Europe)	53	100%	Multidisciplinary team (components differed at each center) involved in patient health education and supervised exercise program	36 m
Ornish et al. (1990) with longer term f/u reported in Ornish et al. (1998)	28	Patients 35-75 yrs with confirmed CAD at least 6 weeks after cardiac event (USA)	58	84%	One week residential program followed by 2 x weekly support meetings relating to low-fat vegetarian diet, stress management, exercise and social support	12 m/60 m
Oldridge et al. (1991)	201	Patients discharged with diagnosis of AMI and evidence of anxiety or depression (Canada)	52	89%	Exercise prescription, supervised training and behavioral counseling	2 m
PRECOR (1991)	182	Males <65 years, discharged after AMI (France)	51	100%	Two intervention arms, one of which was: Comprehensive cardiac rehabilitation (supervised exercise program, relaxation training, risk factor management, education)	1.5 m
Fridlund et al. (1991)	178	Patients <65 years discharged after AMI (Sweden)	56	87%	Nurse-led rehabilitation program addressing lifestyle, stress and social support.	6m
Engblom et al. (1992)	228	Patients younger than 65 years, discharged after CABG (Finland)	54	88%	Group education, individual counseling (with physician and dietician) about diet and	0.75 m

					physical activity, supervised exercise training	
Heidelberg Trial (Schuler et al. 1992 and Niebauer et al. 1997)	113	Males with CAD on angiography (Germany)	54	100%	Education about diet and exercise, exercise program with individual and group training sessions	12 m
Bell (1998)	353 (201 in control and comprehensive secondary prevention arms)	Patients \leq 75 years discharged after AMI (UK)	60	78%	Comprehensive cardiac rehabilitation (supervised exercise program, group education sessions on risk factor management)	3 m
Johnston et al. (1999)	100	Patients \leq 70 years hospitalized for 1 st time myocardial infarction (UK)	56	65%	Nurse-led inpatient and outpatient cardiac rehabilitation program containing education, support for risk factor change and psychological effects.	1.5 m
Lisspers et al. (1999)	93	Patients <65 after PCI (Sweden)	53	37%	Comprehensive residential (health education, behavioral change) containing skills training, habit rehearsal on stress management, smoking, diet, exercise and smoking; followed by outpatient program of self observation and reporting of risk factors with follow up support.	12 m
Toobert et al. (2000)	28	Post menopausal female patients with documented CAD at least 6 weeks after cardiac event	64	0%	Residential program for women and spouse including support for low fat cookery, stress management, supervised exercise, and peer support sessions; followed by 2 x weekly community sessions.	9 m
Seki et al. (2003)	38	Male patients (>65 years) with CAD referred to hospital within past 6 months after MI, CABG or PTCA (Japan)	70	100%	Out patient program including supervised exercise sessions, and prescription, dietary and educational components.	6 m
Sundin et al. (2003)	132	Male patients <70 years after PCI, AMI or CABG (Sweden)	59	100%	Group-based multidisciplinary program addressing stress management, diet and exercise using lectures and skills training	12 m
Yu et al. (2003)	112	Obese patients attending cardiac rehabilitation after acute MI or after	62	79%	Exercise program with group education classes about risk factor modification	2.5 m

		percutaneous coronary intervention (China)				
Vestfold Heartcare Study (2003)	197	Patients discharged after acute coronary syndrome, CABG, PCI (85%); plus patients followed in clinic with stable CAD (15%) (Norway)	55	82%	Supervised exercise program, dietary advice, risk factor management education and individual plus group counseling involving a multidisciplinary team (physician, nurse, dietician, physiotherapist)	24 m
Marchionni et al. (2003)	270	Patients older than 45 years discharged after AMI (Italy)	69	71%	Supervised exercise training and education/counseling about risk factor management, optional monthly support groups	2 m
Group Cardiac Rehabilitation without exercise component (4 trials, 2671 patients)						
Stern et al. (1983)	106 (64 in control and group counseling arms)	Patients aged 30-69 years with recent MI (USA)	54	83%	Nurse and psychiatrist/social worker led group education and counseling sessions (12 sessions)	3 m
PRECOR (1991)	182	Males <65 years, discharged after AMI (France)	51	100%	Two intervention arms, one of which was: Group Counseling Program (group education and counseling led by physician, psychiatrist, and nutritionist)	1.5 m
Jones & West (1996)	2328	Patients discharged home within 28 days of AMI (United Kingdom)	62	73%	Nurse and psychologist regularly saw participants for education, counseling, and relaxation/stress management training	1.75 m
DIET (Masley et al. 2001)	97	Patients with known CAD and hyperlipidemia in specialty clinics (USA)	65	70%	Nurse-led education (group) and provision of written materials about diet and physical activity	12 m
Individual Counseling (24 trials, 11 942 patients)						
Ornish et al. (1983)	23	Patients 45-75 yrs with evidence of CAD as documented in hospital records (USA)	59	78%	Residential program in remote rural location of stress management and low fat dietary meals and training	1 m
SCRIP (Haskell et al. 1994)	300	Patients < 75 yrs referred for angiography for known or suspected CAD (USA)	56	86%	Nurse-managed patient education and algorithm-driven management of risk factors, exercise program, frequent telephone and clinic visits with nurse	48 m
DeBusk et al.	585	Patients ≤ 70 yrs discharged after AMI	57	79%	Nurse-managed patient education and	12 m

(1994) and Taylor et al. (1997)		(USA)			counseling, exercise program, frequent telephone contact, and algorithm-based lipid therapy	
Fitzgerald et al. (1994)	668	Patients > 45 yrs discharged from a general medicine in-patient service (2/3 with heart disease) and being followed at the general medicine clinic of a Veterans Affairs hospital (USA)	65	100%	Nurse-managed patient education, coordination of care, frequent telephone contact, and protocol-driven systematic assessments for unmet socio-medical needs	12 m
Naylor et al. (1994)	276 (142 with cardiac disease)	Patients > 70 yrs discharged from a tertiary care hospital with either CAD or heart failure (USA)	76	49%	Comprehensive discharge planning protocol with gerontologic nurse providing education, coordinating care, and maintaining telephone contact for 2 weeks	0.5 m
Cupples and McKnight (1994 and 99)	688	Patients <75 years with angina for at least 6 months identified from general practice records (UK)	63	59%	Individual nurse-led personalized health promotion program every 4 months	24 m
M-HART (Frasure-Smith et al. 1997)	1376	Patients discharged after AMI (Canada)	59	66%	Nurse contacted patients monthly by telephone, providing education and advice and screening patients for psychological distress- nurses referred patients to other health care resources as needed	12 m
Carlsson et al (1997)	168	Patients aged 50-70 years discharged after AMI (Sweden)	62	75%	Nurse-run education program (individual and group), exercise training program, nurse clinic visits	12 m
Carlsson (1998)	530	Patients aged 50-70 years discharged after AMI, CABG or PCI (Sweden)	62	79%	Individualized assessment and nurse counseling on risk factors and diet	12 m
Campbell et al. (1998), with longer term f/u reported in Murchie et al (2003)	1343	Patients <80 yrs old with documented CAD recruited from general practice records (United Kingdom)	66	58%	Regular follow-up at secondary prevention clinics run by nurses, promoting medical and lifestyle approaches to prevention	12 m
Jolly et al. (1999)	597	Patients with AMI or recent onset angina discharged from hospital or seen in a chest pain clinic (United Kingdom)	64	71%	Cardiac liaison nurse coordinated care between discharging service and family physician, patients given personal health record and prompts for follow-up	12 m
Naylor and	363 (202	Patients \geq 65 years discharged from a	75	50%	Nurse-led patient education, coordination of	1 m

McCauley (1999)	with cardiac disease)	tertiary care hospital with either CAD or heart failure or after CABG/heart surgery (USA)			home care, at least 2 home visits, use of a standardized protocol to optimize medications, and weekly telephone contact for 1 month	
Allison et al. (1999)	152	Patients not treated with lipid lowering medication that completed cardiac rehabilitation after an acute coronary event (USA)	64	82%	Nurse-led follow up program every 6 weeks after start or change in lipid lowering therapy, including diet and exercise advice and lipid lowering medications.	6 m
Allison et al. (2000)	326	Patients attending emergency room with confirmed unstable angina (USA)	58	56%	Nurse-intervention including lipid management, referral to support services, counseling on risk factors and physician collaboration on abnormal results, 2 1-hour sessions at least 6 and 25 days after discharge	1 m
Moher et al. (2001)	1906	Patients 55-75 years identified in family practices with established CAD (UK)	66	68%	Nurse-led clinic providing support for risk factor change using electronic disease register and recall system	1 m
Stagmo et al. (2001)	241	Patients 50-69 years hospitalized in a CCU due to MI or previous CABG (Sweden)	62	78%	Hospital-based secondary prevention program	12 m
McHugh et al. (2001)	98	Patients on a waiting-list for elective CABG (UK)	62	76%	Shared nurse-led care program of monthly health education and motivational interviewing	7 m
Higgins et al. (2001)	105	Patients discharged after PCI (Australia)	48	90%	Nurse-led individualized education, risk factor goal setting and self-monitoring with telephone feedback, 3 home visits	12 m
Allen et al. (2002)	228	Patients \leq 75 years discharged after CABG or PCI who had hypercholesterolemia (USA)	60	63%	Nurse practitioner case management in partnership with patient's primary provider (nurse-directed education and lifestyle modification advice, nurse clinic visits, nurse prescribed medications if necessary, f/u telephone calls)	12 m
COACH pilot (Vale et al. 2002)	245	Patients \leq 75 years discharged after coronary revascularization procedure (Australia)	61	75%	Personal coaching by dietician via 5 telephone sessions and 5 mailings to achieve coronary risk factor targets (education, negotiated lifestyle plan,	6 m

					emphasis on follow-up with primary care provider and empowerment to ask for medication, repeated measurements)	
COACH (Vale et al. 2003)	792	Patients discharged from 6 hospitals after CABG, PCI, AMI, coronary angiography (Australia)	59	77%	Personal coaching (delivered by nurses or dieticians) via 5 telephone sessions and 5 mailings to achieve coronary risk factor targets (education, negotiated lifestyle plan, emphasis on follow-up with primary care provider and empowerment to ask for medication, repeated measurements)	6 m
ELMI Trial (Lear et al. 2003)	302	Patients discharged from 2 tertiary-care cardiac rehabilitation programs (Canada)	64	83%	Personal coaching by case manager delivered via telephone and in-person counseling sessions; if suboptimal coronary risk factors at 6 months, treatment algorithms with cover letter from cardiologist mailed to primary care physicians	12 m
Young et al. (2003)	146	Patients discharged home after AMI (Canada)	69	60%	Patient education, at least 6 home visits by nurse, nurse communication with primary care providers, and nurse-initiated referral for specialty care (based on standardized pathway)	2 m
REACH Trial (Lichtman et al. 2004)	756	Patients aged 30-80 years discharged from tertiary care hospital with documented coronary disease (USA)	64	71%	Nurse-based education and counseling about cholesterol and target levels delivered via telephone (4 calls in 9 m) and mailed educational materials about a variety of secondary prevention maneuvers	12 m

* As outlined in text, the results for 13 of the 24 collaborating centers in the World Health Organization Trial are included here. Reasons for the exclusion of the other 11 centers are given in the text.

CABG = coronary artery bypass grafting; CAD = coronary artery disease; COACH = Coaching patients On Achieving Cardiovascular Health Study; DIET = Dietary Intervention and Evaluation Trial; ELMI = Extensive Lifestyle Management Intervention ; ETICA = Exercise Training Intervention after Coronary Angioplasty; M-HART = Montreal Heart Attack Readjustment Trial; MI = myocardial infarction; NEHDP = National Exercise and Heart Disease Project; NR = not reported; PCI = percutaneous coronary intervention; CCU = coronary care unit; REACH= Reinforcing Education About Cholesterol; SCRIP = Stanford Coronary Risk Intervention Project; UK = United Kingdom; USA = United States.

Table 2: Impact of interventions on all-cause mortality and recurrent myocardial infarctions.

Study	Length of Follow-up	All-cause mortality (#events/total # patients)			Recurrent Myocardial Infarctions* (#events/total # patients)		
		Intervention Arm	Control Arm	Risk Ratio	Intervention Arm	Control Arm	Risk Ratio
Comprehensive Cardiac Rehabilitation							
Sivarajan et al.	6 m	3/86	2/84	1.47 (0.25, 8.55)	NR	NR	NR
Vermeulen et al.	60 m	2/47	5/51	0.43 (0.09, 2.13)	4/47	9/51	0.48 (0.16, 1.46)
Bengtsson	12 m	10/81	6/90	1.85 (0.70, 4.87)	2/81	4/90	0.56 (0.10, 2.95)
WHO	36 m	146/893	161/842	0.86 (0.70, 1.05)	150/893	139/842	1.02 (0.82, 1.26)
Ornish et al. (90,98)	60m	2/28	1/20	1.43 (0.14, 14.70)	25/28	45/20	0.36 (0.07, 1.76)
Oldridge et al.	12 m	3/99	4/102	0.77 (0.18, 3.36)	NR	NR	NR
PRECOR** - comprehensive rehabilitation arm	24 m	0/60	4/61	0.11 (0.01, 2.05)	4/60	6/61	0.68 (0.20, 2.28)
Fridlund et al.	12 m	9/87	14/91	0.67 (0.31, 1.47)	4/87	14/91	0.30 (0.10, 0.87)
Engblom et al.	12 m	12/119	13/109	0.85 (0.40, 1.77)	8/119	16/109	0.46 (0.20, 1.03)
Heidelberg Trial	12 m	2/56	1/57	2.04 (0.19, 21.82)	2/56	4/57	0.51 (0.10, 2.67)
	72 m	5/43	8/53	0.77 (0.27, 2.18)	3/43	4/53	0.92 (0.22, 3.91)
Bell	12 m	7/99	8/102	0.90 (0.34, 2.39)	NR	NR	NR
Lisspers et al.	12 m	0/46	1/41	0.30 (0.01, 7.12)	NR	NR	NR
Vestfold Heartcare Study	24 m	2/98	1/99	2.02 (0.19, 21.92)	4/99	3/99	1.33 (0.72, 1.05)
Marchionni et al.	12 m	7/180	3/90	1.17 (0.31, 4.41)	1/180	3/90	0.17 (0.02, 1.58)
Sub-Total:	14 trials	208/1966	231/1835	0.86 (0.73, 1.03)	182/1637	202/1506	0.64 (0.43, 0.95)
Group Cardiac Rehabilitation without exercise component							
Stern et al.	12 m	0/35	1/29	0.28 (0.01, 6.57)	3/35	2/29	1.24 (0.22, 6.94)
PRECOR** -counseling arm	24 m	5/61	4/61	1.25 (0.35, 4.43)	4/61	6/61	0.67 (0.20, 2.25)
Jones & West	12 m	79/1168	84/1160	0.93 (0.69, 1.26)	43/1168	48/1160	0.89 (0.59, 1.33)
Sub-Total:	3 trials	84/1264	89/1250	0.94 (0.70, 1.25)	50/1264	56/1250	0.88 (0.61, 1.28)

Individual Counselling							
SCRIP	12 m	1/145	0/155	3.21 (0.13, 78.06)	5/145	0/155	11.75 (0.66, 210.69)
	24 m	1/145	2/155	0.53 (0.05, 5.83)	5/145	3/155	1.78 (0.43, 7.32)
	36 m	2/145	2/155	1.07 (0.15, 7.49)	5/145	6/155	0.89 (0.28, 2.86)
	48 m	3/145	3/155	1.07 (0.22, 5.21)	6/145	11/155	0.58 (0.22, 1.54)
DeBusk et al. and Taylor et al. (1997)	12 m	12/293	10/292	1.20 (0.52, 2.72)	10/293	20/292	0.50 (0.24, 1.05)
Fitzgerald et al.	12 m	35/333	35/335	1.01 (0.65, 1.57)	NR	NR	NR
Cupples & McKnight	24 m	13/342	29/346	0.45 (0.24, 0.86)	NR	NR	NR
	60 m	47/342	65/346	0.73 (0.52, 1.03)	NR	NR	NR
M-HART	12 m	38/692	27/684	1.39 (0.86, 2.25)	44/692	42/684	1.04 (0.69, 1.56)
Carlsson (1998)	12 m	2/118	2/117	0.99 (0.14, 6.92)	NR	NR	NR
Campbell et al.	12 m	22/673	25/670	0.88 (0.50, 1.54)	13/540	12/518	1.04 (0.48, 2.26)
	56 m	100/673	128/670	0.78 (0.61, 0.99)	100/673	125/670	0.80 (0.63, 1.01)
Jolly et al.	12 m	15/277	23/320	0.75 (0.40, 1.42)	NR	NR	NR
Allison et al. (2000)	6m	2/158	2/168	1.06 (0.15, 7.46)	0/158	1/168	0.35 (0.01, 8.63)
COACH pilot	6 m	0/121	2/124	0.20 (0.01, 4.22)	NR	NR	NR
COACH	6 m	4/398	4/394	0.99 (0.25, 3.93)	NR	NR	NR
	48 m	32/398	32/394		NR	NR	NR
ELMI	12 m	1/151	3/151	0.33 (0.04, 3.17)	NR	NR	NR
Young et al.	14 m	8/71	11/75	0.77 (0.33, 1.80)	NR	NR	NR
Sub-Total:	13 trials	295/3772	343/3831	0.86 (0.75, 1.00)	160/1961	199/1969	0.81 (0.66, 0.98)
TOTAL	29 trials**						
-closest to 12m data		442/7015	482/6859	0.90 (0.79, 1.01)	303/4742	327/4516	0.80 (0.65, 0.99)
-over entire study		587/7002	659/6855	0.87 (0.79, 0.97)	392/4862	451/4664	0.83 (0.72, 0.96)

For trials with outcomes reported at various timepoints, the longest duration of follow-up data was used for generating the pooled sub-total estimates. The pooled total estimates are presented for both the “12 month or closest to 12 month data” as well as “longest duration of follow-up in each trial”. NR= not reported

* Data for all trials except that of Campbell et al., DeBusk et al., and Allison et al. are for the combined endpoint of nonfatal and fatal myocardial infarction. The Campbell et al. trial only collected data on nonfatal reinfarction rate and total mortality (they were unable to dissect out causes of mortality). The Allison et al. and DeBusk et al. trials collected data on nonfatal myocardial infarction.

** Note that for PRECOR, there were 2 intervention arms and 1 control arm. The control arm data has been included only once in the "TOTAL" pooled estimate.

Table 3: Impact of interventions on other endpoints

Study	Major Cardiovascular Risk Factors			Use of proven efficacious therapies	Patient Quality of Life	Patient functional status or symptom scores
	Cholesterol	Smoking	BP			
Comprehensive Cardiac Rehabilitation						
Sivarajan et al.	NR	NR	NR	NR	NR	NR
Vermeulen et al.	++	0	NR	NR	NR	+
Bengtsson	NR	NR	++	NR	0	NR
WHO*	++	-	++	++	NR	0
Ornish et al. (90, 98)	++	NR	0	NR	NR	++
Oldridge et al.	NR	NR	NR	NR	+	0
PRECOR - comprehensive rehabilitation arm	NR	0	NR	NR	NR	++
Fridlund et al.	NR	0	NR	NR	++	++
Engblom et al.	0	++	0	0	++	NR
Heidelberg Trial -12 m f/u -72 m f/u	++ 0	0 0	NR NR	0 0	NR NR	NR NR
Johnston et al.	NR	NR	NR	NR	++	++
Lisspers et al.	NR	++	NR	NR	NR	NR
Toobert et al.	0	+	+	NR	++	++
Seki et. al.	NR	NR	NR	NR	++	0
Sundin et al.	+	NR	NR	NR	NR	NR
Yu et al.	NR	NR	NR	NR	+	+
Vestfold Heartcare Study	0	++	0	0	++	++
Marchionni et al.	NR	NR	NR	NR	NR	++
Group Cardiac Rehabilitation without exercise component						
Stern et al.	NR	NR	NR	NR	++	NR
PRECOR -counseling arm	NR	0	NR	NR	NR	++

Jones & West	NR	0	NR	0	0	0
DIET	+	NR	NR	NR	NR	NR
Individual Counselling						
Ornish et al. (83)	++	+	NR	NR	NR	++
SCRIP	++	++	+	++	NR	NR
DeBusk et al. and Taylor et al. (1997)	++	++	NR	++	NR	++
Fitzgerald et al.	NR	NR	NR	NR	NR	NR
Naylor et al. (94)	NR	NR	NR	NR	0	0
Cupples & McKnight	+	+	+	++	NR	++
M-HART	NR	NR	NR	NR	+	NR
huCarlsson et al. (1997)	NR	+	NR	NR	NR	NR
Carlsson (1998)	++	NR	NR	++	NR	NR
Campbell et al. -12m f/u	++	0	++	++	++	++
-56 m year f/u	+	0	+	0	0	0
Jolly et al.	+	0	+	0	0	0
Naylor & McCauley (99)	NR	NR	NR	NR	+	+
Allison et al. (99)	+	++	NR	++	NR	NR
Allison et al. (2000)	+	0	0	0	NR	NR
Moher et al	++	++	++	0	0	NR
Stagmo et al.	+	NR	NR	+	NR	NR
McHugh et al.	++	++	++	NR	++	++
Higgins et al.	+	0	NR	NR	NR	++
Allen et al.	++	NR	NR	+	NR	NR
COACH pilot	++	NR	NR	0	NR	NR
COACH	++	0	++	++	++	++
ELMI	0	0	0	NR	0	0
Young et al.	NR	NR	NR	NR	NR	NR
REACH	0	NR	NR	0	NR	NR

Use of proven efficacious therapies” encompasses both increased prescription rate by clinicians and/or increased compliance by patients.”

++ Statistically significant benefit seen in the intervention arm vs. control arm.

+ Trend towards better outcomes in the intervention arm, but didn't reach statistical significance.

0 No appreciable difference between the intervention arm and control arm.

NR Not reported in study.

Table 4. Methodologic Quality of Included Studies

Study	Described as Randomized	Method of Randomization Described and Appropriate	Description of Withdrawals or Losses to Follow-Up	Jadad Score	Allocation Concealment
Comprehensive Cardiac Rehabilitation					
Sivarajan et al.	Yes	No	Yes	2	Unclear
Vermeulen et al.	Yes	No	Yes	2	Unclear
Bengtsson	Yes	No	Yes	2	Unclear
WHO trial	Yes	Yes	No	2	Unclear
Ornish et al. (90, 98)	Yes	No	Yes	2	Unclear
Oldridge et al.	Yes	No	No	1	Unclear
PRECOR.,	Yes	No	Yes	2	Unclear
Fridlund et al.	Yes	No	Yes	2	Unclear
Engblom et al.	Yes	No	No	1	Unclear
Heidelberg Trial	Yes	No	Yes	2	Adequate
Bell	Yes	No	Yes	2	Unclear
Johnston et al.	Yes	No	Yes	2	Unclear
Lisspers et al.	Yes	No	Yes	2	Unclear
Toobert et al.	Yes	No	Yes	2	Unclear
Seki et al.	Yes	No	Yes	2	Adequate
Sundin et al.	Yes	No	No	1	Unclear
Yu et al	Yes	No	No	1	Unclear
Vestfold Heartcare	Yes	No	No	1	Adequate
Marchionni et al.	Yes	No	Yes	2	Unclear
Cardiac rehabilitation					
Stern et al.	Yes	No	No	1	Unclear
PRECOR.	Yes	No	Yes	2	Unclear
Jones and West	Yes	No	Yes	2	Adequate
D.I.E.T.	Yes	No	No	1	Unclear
Individual counseling					
Ornish et al. (83)	Yes	Yes	No	2	Unclear

SCRIP	Yes	Yes	Yes	3	Adequate
DeBusk et al.; Taylor et al. (97)	Yes	Yes	Yes	3	Adequate
Fitzgerald et al.	Yes	No	Yes	2	Unclear
Naylor et al. (94)	Yes	No	Yes	2	Unclear
Cupples and McKnight	Yes	Yes	Yes	3	Adequate
M-HART	Yes	No	Yes	2	Adequate
Carlsson et al.	Yes	No	Yes	2	Unclear
Campbell et al.	Yes	Yes	Yes	3	Adequate
Jolly et al.	Yes	No	Yes	2	Adequate
Naylor and McCauley (99)	Yes	Yes	Yes	3	Adequate
Allison et al. (99)	Yes	No	Yes	2	Unclear
Allison et al. (00)	Yes	Yes	No	2	Unclear
Moher et al.	Yes	Yes	Yes	3	Unclear
Stagmo et al.	Yes	No	Yes	2	Unclear
McHugh et al.	Yes	No	Yes	2	Unclear
Higgins et al.	Yes	No	Yes	2	Unclear
Allen et al.	Yes	Yes	Yes	3	Unclear
COACH pilot	Yes	No	Yes	2	Unclear
COACH	Yes	Yes	Yes	3	Unclear
ELMI	Yes	Yes	Yes	3	Unclear
Young et al.	Yes	Yes	Yes	3	Adequate
REACH	Yes	Yes	Yes	3	Unclear

*When there were several publications for the same study, quality assessment was done by using the primary publication. COACH = Coaching patients On Achieving Cardiovascular Health Study; DIET = Dietary Intervention and Evaluation Trial; ELMI = Extensive Lifestyle Management Intervention ; ETICA = Exercise Training Intervention after Coronary Angioplasty; M-HART = Montreal Heart Attack Readjustment Trial; NEHDP = National Exercise and Heart Disease Project; REACH= Reinforcing Education About Cholesterol; SCRIP = Stanford Coronary Risk Intervention Project.

Table 5a: Characteristics of Comprehensive Cardiac Rehabilitation Programs

Study	Location	Time to initiation (weeks)	Mean Length (weeks)	Total time (hours)	Individualization degree	Physician Involvement	Theo Basis	Nurs / Pharm Prescribing	Phone Support	Specialist Profs	Based on stated guidelines/ protocol
Sivarajan et al.	Hosp	0	13	14.5	3	ETT	X	X	X	•	X
Vermeulen et al.	Hosp	6	6	---	2	ETT	X	X	X	---	X
Bengtsson	Hosp	4	16	---	2	ETT	X	X	X	•	X
WHO	Hosp	2	156	---	4	Follow up	X	X	X	•	X
Ornish et al. (1990, 1998)	Comb	6	52	1040	3	Coord	X	X	•	•	•
Oldridge et al.	Hosp	6	8	12	2	ETT	X	X	X	•	X
PRECOR	Hosp	8	6	9	3	Teaching	X	X	X	•	X
Fridlund et al.	Hosp	0	26	52	3	Teaching	X	X	X	•	X
Engblom et al.	Hosp	0	52	59	2	ETT	X	X	X	X	X
Heidelberg Trial	Hosp	---	312	---	2	ETT	X	X	X	X	---
Bell	Hosp	8	---	---	2	ETT	X	X	X	X	X
Johnston et al.	Hosp	1	8	9	3	ETT	X	X	X	•	X
Lisspers et al.	Comb	2	52	140	2	ETT	•	X	•	•	X
Toobert et al.	Comb	26	104	117	3	Screening	X	X	X	•	X
Seki et al.	Hosp	204	26	26	3	Coord	X	X	X	•	X
Sundin et al.	Comb	---	52	51	2	ETT	•	X	X	•	X
Yu et al.	Comb	6	10	48	2	NONE	X	X	X	X	X
Vestfold Heartcare Study	Comb	6	104	50	2	Coord	•	X	X	•	•
Marchionni et al.	Comb	6	8	38	3	NONE	X	X	X	•	•

Table 5b: Characteristics of Group Cardiac Rehabilitation Without Exercise Component Programs

Study	Location	Time to initiation (weeks)	Mean Length (weeks)	Total time (hours)	Individualization degree	Physician Involvement	Theo Basis	Nurs / Pharm Prescribing	Phone Support	Specialist Profs	Based on stated guidelines/ protocol
Stern	Hosp	52	12	13.5	2	ETT	X	X	X	X	X
PRECOR	Hosp	8	6	9	3	Teaching	X	X	X	•	X
Jones and West	Hosp	4	7	14	3	NONE	X	X	X	•	X
DIET	Comb	---	52	18	2	ETT	X	X	X	X	X

Table 5c: Characteristics of Individual Counseling Programs

Study	Location	Time to Initiation (weeks)	Mean Length (weeks)	Total time (hours)	Individualization degree	Physician Involvement	Theo Basis	Nurs / Pharm Prescribing	Phone Support	Specialist Profs	Based on stated guidelines / protocol
Ornish (1983)	Residential	6	3	37.5	3	Coord	X	X	•	•	X
SCRIP	Hosp	21	208	60	5	ETT	X	X	•	•	•
DeBusk et al.	Hosp	16	52	9	4	NONE	•	•	•	•	X
Fitzgerald et al.	Hosp	1	12	19	2	Screening	X	X	•	•	X
Naylor et al.	Hosp	0	2	4	4	ETT	X	X	•	•	X
Cupples and McKnight	GP	406	104	2	5	NONE	X	X	X	X	X
M---HART	Home	1	52	12	4	ETT	X	X	•	•	•
Carlsson et al. (1997)	Hosp	4	11	24	4	Follow up	X	X	X	•	X
Carlsson (1998)	Hosp	4	52	26	3	Follow up	X	X	X	•	X
Campbell et al.	GP	312	52	4.1	3	ETT	X	•	•	•	•
Jolly et al.	GP	0	52	---	3	ETT	•	X	•	•	X
Naylor and McCauley	Comb	0	4	4	3	ETT	X	X	•	X	X
Allison (1999)	Hosp	12	4	16	3	Follow up	X	•	X	•	•
Allison (2000)	Hosp	2	26	2	3	ETT	X	•	X	•	X
Moher et al.	GP	---	78	---	0	NONE	X	•	---	---	---
Stagmo et al.	Hosp	6	52	5.75	3	Follow up	X	X	X	•	•
McHugh et al.	Comb	---	---	---	5	ETT	•	X	•	•	•
Higgins et al.	Home	1	52	6	5	ETT	•	X	•	•	X
Allen et al.	Home	0	52	4.5	4	Lipid mment	X	•	•	•	X
COACH PILOT	Home	2	26	1.5	5	ETT	X	X	•	•	3
COACH	Hosp	2	24	1.5	2	ETT	X	X	•	•	X
ELMI	Hosp	8	16	40	3	NONE	X	X	•	•	•
Young	Home	1	8	6	3	NONE	X	X	X	•	X
REACH	Home	0	52	0.5	3	ETT	X	X	•	•	X

Table 6: Number of trials with age-based exclusion criteria

Upper age limit (years)	Number of studies
>79	2
75-79	8
70-74	6
65-69	8
60-64	0
55-59	1
No upper age-based criteria used	21

Table 7: Proportion of women in trials

Proportion of women	Number of studies
0 %	8
1%-10%	2
11%-20%	11
21-30%	13
31-40%	6
41-50%	3
51-60%	1
>61%	2


Figure 1: Flow of trials through the selection process

Figure 2: All-cause mortality in trials evaluating comprehensive cardiac rehabilitation




Figure 3: All-cause mortality in trials evaluating group cardiac rehabilitation without exercise component




Figure 4: All-cause mortality in trials evaluating individual counseling




Figure 5: Recurrent myocardial infarctions in trials evaluating comprehensive cardiac rehabilitation




Figure 6: Recurrent myocardial infarctions in trials evaluating group cardiac rehabilitation without exercise component




Figure 7: Recurrent myocardial infarctions in trials evaluating individual counseling





Figure 8: Hospitalization rates in trials evaluating secondary prevention programs

These data depict risk ratios for the number of patients requiring at least one hospitalization during follow-up. $\text{RR} < 1$ are consistent with less hospitalizations in the intervention arm; $\text{RR} > 1$ are associated with less hospitalizations in the control arm. Note that the data from some studies (SCRIP, Heidelberg, M-HART, Allison, and COACH) are “cardiovascular hospitalizations” while for the other studies it is “all-cause hospitalizations”. The “all-cause hospitalization” summary RR was 0.84 (95% CI 0.74-0.97) in 9 trials ($n=3653$) and the “cardiovascular hospitalization” summary RR was 0.76 (95% CI 0.58-0.98) in 7 studies ($n=3233$).

Figure 9: Funnel Plot for all-cause mortality data




Figure 10: Survey steps




Figure 11: All-cause mortality stratified by length of program (expressed in hours)

Review: Secondary prevention programmes in coronary heart disease (AHRQ part 2)
 Comparison: 02 All-Cause Mortality
 Outcome: 19 All programs by number of sessions




Figure 12: All-cause mortality stratified by degree of health care provider specialization

Review: Secondary prevention programmes in coronary heart disease (AHRQ part 2)
 Comparison: 02 All-Cause Mortality
 Outcome: 17 All programs by instructor




Figure 13: All-cause hospitalizations stratified by degree of individualization





Figure 14: All-cause hospitalizations stratified by nurse prescribing



Appendix A. Search Strategies

MEDLINE - Ovid Version: rel9.1.0

Searched December 16, 2004

Results: 2527 unique records

1. exp "Case Management"/
2. exp "Comprehensive Health Care"/
3. exp "Disease Management"/
4. exp "Health Services Research"/
5. exp "Home Care Services"/
6. exp "Clinical Protocols"/
7. exp "Patient Care Planning"/
8. exp "Quality of Health Care"/
9. exp REHABILITATION/
10. (nurse adj led adj1 clinic\$).ti,ab.
11. (special\$ adj1 clinic\$).ti,ab.
12. or/1-11
13. exp "Myocardial Ischemia"/ or "Myocardial Ischemia\$".ti,ab.
14. RANDOMIZED CONTROLLED TRIAL.pt.
15. ANIMAL/ not HUMAN/
16. 14 not 15
17. 12 and 13 and 16
18. limit 17 to (english language and yr=1999 - 2005)
19. remove duplicates from 18

- The same search was conducted in **EBM Reviews - Cochrane Central Register of Controlled Trials - Ovid Version: rel9.1.0** (4th Quarter 2004) on December 16, 2004.
- There were 141 unique results.

PubMed

Searched December 16, 2004

Results: 50 unique records

The following search was conducted:

("Case Management"[MeSH] OR "Comprehensive Health Care"[MeSH] OR "Disease Management"[MeSH] OR "Health Services Research"[MeSH] OR "Home Care Services"[MeSH] OR "Clinical Protocols"[MeSH] OR "Clinical Protocols"[MeSH] OR "Patient Care Planning"[MeSH] OR "Quality of Health Care"[MeSH] OR "Rehabilitation"[MeSH]) AND ("Myocardial Ischemia"[MeSH] OR Myocardial Ischemia Field: Title/Abstract)

Limits: Publication Date from 2004/01/01 to 2004/12/17, Randomized Controlled Trial

Web of Science

Searched December 17, 2004

Results: 606 unique records

The **Cited Reference Search** feature was used to search for studies that cited the included studies from the original article.

EMBASE - Ovid Version: rel9.1.0

1988 to 2004 Week 51

Searched December 20, 2004

Results: 1313 unique records

1. exp "Patient Care"/
2. exp "Health Care"/
3. exp "Disease Management"/
4. exp "Health Services Research"/
5. exp "Home Care"/
6. exp "Clinical Protocol"/
7. exp "Health Care Quality"/
8. exp REHABILITATION/
9. (nurse adj led adj1 clinic\$.ti,ab.
10. (special\$ adj1 clinic\$.ti,ab.
11. or/1-10
12. exp "Heart Muscle Ischemia"/ or exp "Ischemic Heart Disease"/ or exp "Coronary Heart Disease"/ or "Myocardial Ischemia\$.ti,ab.
13. RANDOMIZED CONTROLLED TRIAL/
14. 11 and 12 and 13
15. limit 14 to english
16. limit 15 to human
17. remove duplicates from 16
18. limit 17 to yr=1999 - 2005

CINAHL (Cumulative Index to Nursing & Allied Health Literature) - Ovid Version: rel9.1.0

1982 to December Week 2 2004

Searched December 21, 2004

Results: 9 unique records

1. exp "Case Management"/
2. *Health Care Delivery/

3. exp "Disease Management"/
4. exp "Health Services Research"/
5. exp Home Health Care/
6. exp Protocols/
7. exp "Quality of Health Care"/
8. exp REHABILITATION/
9. (nurse adj led adj1 clinic\$).ti,ab.
10. (special\$ adj1 clinic\$).ti,ab.
11. or/1-10
12. exp "Myocardial Ischemia"/ or "Myocardial Ischemia\$".ti,ab.
13. clinical trial.pt.
14. animals/
15. 13 not 14
16. and/11-12,15
17. limit 16 to yr=1999-2005

SIGLE - FIZ Karlsruhe – Version Interhost 3000

Searched December 21, 2004

Results: 53

CORONARY OR MYOCARDIAL

AND

Health services, health administration, community care services

Appendix B: List of Excluded Studies and Reasons for Exclusion (full references at end of table)

Author year	Source	Reason for exclusion
Ades and Coello 2000	Database (WOS)	Guideline / review article
Akosah, Schaper, Havlik et al 2002	Database	Not randomized
Aldana, Whitmer, Greenlaw et al 2003	CMS	Not randomized
Ammerman, Keyserling, Atwood et al 2003	Database (Medline)	Primary prevention
Angerer, Siebert, Kothny et al 2000	CMS	Not randomized
Anonymous 1982	Database	Primary prevention
Ariyo, Haan, Tangen et al 2000	CMS	Not randomized
Arthur, Daniels, McKelvie 2000	Database (Medline)	Did not report primary outcomes
Barnard, Massey, Cherny et al 1983	CMS	Evaluated interventions which were not comprehensive disease management systems
Barnes, Trieber, Turner et al 1999	CMS	Population not CHD
Bartels, Gerdes, Babin-Ebell et al 2002	CMS	Guideline / review article
Beckie 1989	Database	Did not report primary outcomes
Bennett, Blackall, Clapham et al 1989	Database	Not randomized
Bentsson 1983	Database	Methodological flaw (patients excluded after randomization)
Berglund, Nilsson, Ericksson et al 2000	Database	Primary prevention
Berkman, Blumenthal, Burg et al 2003	Database (Medline)	Evaluated interventions which were not comprehensive disease management systems
Bethell and Mullee 1990	Reference list	Evaluated interventions which were not comprehensive disease management systems
Billings, Scherwitz, Sullivan et al 1996	CMS	Guideline / review article
Bjarnason-Wehrens, Benesch, Bischoff et al 2003	Database (WOS)	Non-English
Blair, Bryant, Bocuzzi 1988	Database	Not randomized
Blumenthal, Jiang, Babyak et al 1997	CMS	Not randomized
Bogden, Koontz, Williamson et	Database	Did not report primary outcomes

al 1997		
Boulay and Prud'homme 2004	Database (WOS)	Not randomized
Bramlet, King, Young et al 1997	Database	Not randomized
Brown, Zhao, Chait et al 2001	CMS	Drug interventions
Burell 1996	CMS	Guideline / review article
Cambien, Richard, Ducimetiere et al 1981	Database	Primary prevention
Campbell, Ritchie, Thain et al 1998	Database (Embase)	Protocol only
Cannon, Braunwald, McCabe et al 2004	CMS	Evaluated interventions which were not comprehensive disease management systems
Caracciolo, Davis, Sopko et al 1995	CMS	Not randomized
Carlson, Johnson, Franklin et al 2000	Database (WOS)	No usual care arm
Carney, Blumenthal, Stein et al 2001	CMS	Not randomized
Castillo-Richmond, Schneider, Alexander et al 2000	CMS	Evaluated interventions which were not comprehensive disease management systems
Chinaglia, Gaschino, Asteggiano et al 2002	Database	Not randomized
Clark, Bakhai, Lacey et al 2004	CMS	Not randomized
Coleman, Grothaus, Sandhu et al 1999	Database	Did not report the outcomes for patients with CHD separately
Corti, Fuster, Fayad et al 2002	CMS	Drug interventions
Coull, Taylor, Elton et al 2004	Database (Medline)	Evaluated interventions which were not comprehensive disease management systems
Council on Clinical Cardiology and Council on Nutrition, Physical Activity and Metabolism 2003	CMS	Guideline / review article
Cummings, Hughes, Weaver et al 1990	Database	Did not report the outcomes for patients with CHD separately
Cundiff 2002	CMS	Guideline / review article
DeBusk, Haskell, Miller et al 1985	Database	Evaluated interventions which were not comprehensive disease management systems
DeBusk, Miller, Parker et al 2004	Database (WOS)	Population not CHD
De Lorgeril, Salen, Martin et al 1999	CMS	Evaluated interventions which were not comprehensive disease management systems

Denollet and Brutsaert 2001	CMS	Not randomized
Detry, Vierendel, Vanbutsele et al 2001	Database (WOS)	Not randomized
DeVries, Palmer, Scheib et al 2002	CMS	Not randomized
DeVries, Day, Scott 2003	CMS	Not randomized
Diehl 1998	CMS	Not randomized
Dugan, Cohen 1998	CMS	Guideline / review article
Dugmore, Tipson, Phillips et al 1999	Database (Medline)	Evaluated interventions which were not comprehensive disease management systems
Eaker, Sullivan, Kelly-Hayes et al 2004	CMS	Not randomized
Eddy 2000	CMS	Guideline / review article
Ellingsen, Hjermann, Abdelnoor et al 2003	Database (Medline)	Primary prevention
Elliott-Eller, Weidner, Pischke 2003	CMS	Abstract
Engblom, Korpilahti, Hamalainen et al 1997	Database	Did not report primary outcomes
Esposito, Giugliano, Nappo et al 2004	CMS	Drug interventions
Esselstyn 1999	CMS	Guideline / review article
Family Heart Study Group 1994	Database	Primary prevention
Fields, Walton, Schneider et al 2002	CMS	Protocol only
Flanagan, Cox, Paine et al 1999	Database	Not randomized
Frasure-Smith and Prince 1985	Database	Not randomized
Frasure-Smith, Lesperance, Gravel et al 2000	CMS	Not randomized
Friedman, Thoreson, Gill et al 1984	Database	Not randomized
Galatius, Gustafsson, Kistorp et al 2003	Database	Not randomized
Geil, Anderson, Gustafson 1995	CMS	Evaluated interventions which were not comprehensive disease management systems
George and Goldberg 2001	CMS	Guideline / review article
Ghoncheh and Smith 2004	CMS	Population not CHD
Gielen, Schuler, Hambrecht 2001	CMS	Guideline / review article
Gleason, Bourdet, Koehn et al 2002	CMS	Not randomized
Gould, Ornish, Scherwitz et al 1995	CMS	Duplicate publication (same study population and follow-up period)

		as Ornish 1998)
Gould, Ornish, Kirkeeide et al 1992	CMS	Protocol only
Grimm for the MRFIT 1983	Database	Primary prevention
Grundy, Cleeman, Merz et al 2004	CMS	Guideline / review article
Gulati, Pandey, Arnsdorf et al 2003	CMS	Not randomized
Hakim, Curb, Petrovitch et al 1999	CMS	Evaluated interventions which were not comprehensive disease management systems
Hambrecht, Walther, Mobius-Winkler 2004	CMS	Evaluated interventions which were not comprehensive disease management systems
Harris, Record, Gipson et al 1998	Database	Not randomized
Hedback and Perk 1987	Database	Not randomized
Imperial Cancer Research Fund OXCHECK Study Group 1995	Database	Primary prevention
Jain, Uppal, Bhatnagar et al 1993	CMS	Evaluated interventions which were not comprehensive disease management systems
Jukema, Bruschke, van Boven et al 1995	CMS	Drug interventions
Kawachi, Sparrow, Vokonas et al 1994	CMS	Not randomized
Ketola, Makela, Klockars 2001	Database (WOS)	Primary prevention
Koertge, Weidner, Billings et al 2002	CMS	Abstract
Koertge, Weidner, Elliott-Eller et al 2003	CMS	Not randomized
Kornitzer, De Backer, Dramaix et al 1980	Database	Primary prevention
Krachler 1997	Reference list	Did not report primary outcomes
Kris-Etherton, Harris, Appel et al 2002	CMS	Guideline / review article
Lampert, Joska, Burg et al 2002	CMS	Not randomized
Lear, Ignaszewski, Linden et al 2002	Database (WOS)	Protocol only
Lesperance, Frasure-Smith, Talajic et al 2002	CMS	Not randomized
Lewin, Furze, Robinson et al 2002	Database (Medline)	No usual care arm
Lewis and Resnik 1967	Database	Did not report the outcomes for

		patients with CHD separately
Liao, Ma, Dong et al 2003	Database (Embase)	Non-English
Lichtenstein and Van Horn 1998	CMS	Guideline / review article
Lindholm, Ekblom, Dash et al 1995	Database	Primary prevention
Maggioni 2000	Database (Embase)	Guideline / review article
Malach and Imperato 2004	CMS	Not randomized
Marra, Paolillo, Spadaccini et al 1985	Database	Evaluated interventions which were not comprehensive disease management systems
Marshall, Penckofer, Llewellyn 1986	Database	Not randomized
Matthews, Gump, Harris et al 2004	CMS	Not randomized
Meer 1999	Database (SIGLE)	Not randomized
Meland, Laerum, Ulvik 1997	Database	Primary prevention
Merritt, Scherwitz, Brown et al 1990	CMS	Abstract
Merritt, Ornish, Scherwitz et al 1995a	CMS	Abstract
Merritt, Ornish, Scherwitz et al 1995b	CMS	Abstract
Merritt-Worden, Pettengill, Ornish 2003	CMS	Abstract
Miettinen, Pyorala, Olsson et al 1997	CMS	Drug interventions
Miller, Erlinger, Young et al 2002	CMS	Non-CHD population
Mittleman, Maclure, Sherwood et al 1995	CMS	Not randomized
National Cholesterol Education Program, National Institutes of Health 2002	CMS	Guidelines / review article
Ness, Hughes, Elwood et al 2002	Database (Medline)	Evaluated interventions which were not comprehensive disease management systems
Nicholson, Sklar, Barnard et al 1999	CMS	Evaluated interventions which were not comprehensive disease management systems
Oldenburg, Martin, Greenwood 1995	Database	Did not report primary outcomes
Ornish 1998	CMS	Not randomized
Ornish 2002	CMS	Guideline / review article

Ornish and Pettengill 2003	CMS	Abstract
Ornish 2004	CMS	Guideline / review article
Ornish (chapter 8)	CMS	Guideline / review article
Ornish and Hart (chapter 34)	CMS	Guideline / review article
Pater, Ditlef Jacobsen, Rollag et al 2000	Database (Embase)	Protocol only (no data presented)
Peiss, Kurleto, Rubenfire 1995	Database	Not randomized
Pettengill, Pearson, Pifalo et al 2002	CMS	Abstract
Pfisterer, Buser, Osswald et al 2003	CMS	Not randomized
Picard, Schwartz, Ahn et al 1989	Database	Evaluated interventions which were not comprehensive disease management systems
Pischke, Weidner, Billings J et al 2002	CMS	Abstract
Pitt, Waters, Brown et al 1999	CMS	Drug interventions
Pollock, Franklin, Balady et al 2000	CMS	Guideline / review article
Pozen, Stechmiller, Harris et al 1977	Database	Inpatient-based intervention
Prochaska, Johnson, Lee	CMS	Guideline / review article
Pyke, Wood, Kinmonth et al 1997	Database	Primary prevention
Rahe, Ward, Hayes 1979	Database	Did not report primary outcomes
Rihal, Raco, Gersh et al 2003	CMS	Guideline / review article
Roderick, Ruddock, Hunt et al 1997	Database	Primary prevention
Roman, Gutierrez, Luksic et al 1983	Database	Evaluated interventions which were not comprehensive disease management systems
Rose, Heller, Pedoe et al 1980	Database	Primary prevention
Rubenstein, Kahn, Reinisch et al 1990	Database	Not randomized
Ruo, Rumsfeld, Hlatky et al 2003	CMS	Not randomized
Scandinavian Simvastatin Survival Study 1994	CMS	Drug interventions
Schectman, Wolff, Byrd et al 1996	Database	Did not report the outcomes for patients with CHD separately
Schneider, Staggers, Alexander et al 1995	CMS	Evaluated interventions which were not comprehensive disease management systems
Sdringola, Nakagawa, Nakagawa et al 2003	CMS	Not randomized

Shaffer and Wexler 1995	Database	Not randomized
Shintani, Beckham, Brown et al 2001	CMS	Population not CHD
Simpson, Dixon, Bolli 2004	Database (WOS)	Not randomized
Sivarajan, Newton, Almes et al 1983	Database	Did not report primary outcomes
The South East London Screening Study Group 1977	Database	Primary prevention
Specchia, De Servi, Scire et al 1996	Reference list	No usual care arm
Stahle, Mattsson, Ryden et al 1999	Database (Medline)	Evaluated interventions which were not comprehensive disease management systems
Starkey, Michaelis, Lusignan 2000	Database	Not randomized
Stern and Cleary 1982	Database	Evaluated interventions which were not comprehensive disease management systems
Strandberg, Pitkala, Berglind et al 2001	Database (Embase)	Protocol only (no data presented)
Taddei, Galetta, Viridis et al 2000	CMS	Evaluated interventions which were not comprehensive disease management systems
Thoresen, Friedman, Gill et al 1982	Database	Not randomized
Townsend, Piper, Frank et al 1988	Database	Evaluated interventions which were not comprehensive disease management systems
Tu, Pashos, Naylor et al 1997	CMS	Not randomized
Vale, Jelinek, Best et al 2003	Database (Medline)	Summary of trial already included
Van Drenth, Hulscher, Mookink et al 1997	Database	Not randomized
Vedin, Wilhelmsson, Tibblin et al 1976	Database	Not randomized
Von Birgelen, Hartmann, Mintz et al 2003	CMS	Not randomized
Wallner, Watzinger, Lindschinger et al 1999	Database (Medline)	No usual care arm
Wasson, Gaudette, Whaley et al 1992	Database	Evaluated interventions which were not comprehensive disease management systems
Waters, Higginson, Gladstone et al 1994	CMS	Drug interventions

Weber, Barnard, Roy 1983	CMS	Population not CHD
Weidner, Pischke, Eller 2003	CMS	Abstract
Weinberger, Smith, Katz et al 1988	Database	Did not report the outcomes for patients with CHD separately
Weingarten, Reidinger, Conner et al 1994	Database	Inpatient-based intervention
Weintraub, Clements, Crisco et al 2003	CMS	Not randomized
Williams, Paton, Siegler et al 2000	CMS	Not randomized
Woollard, Burke, Beilin et al (Journal of Cardiovascular Risk) 2003	Database (Medline)	Did not report the outcomes for patients with CHD separately
Woollard, Burke, Beilin (Journal of Human Hypertension) 2003	Database (WOS)	Did not report the outcomes for patients with CHD separately
Yu-Poth, Zhao, Etherton et al 1999	CMS	Guideline / review article

Full Citations for **Excluded Studies**

- Ades PA, Coello CE. Effects of exercise and cardiac rehabilitation on cardiovascular outcomes. *Med Clin North Am* 2000 Jan;84(1):251-65, x-xi.
- Akosah KO, Schaper AM, Havlik P, Barnhart S, Devine S. Improving care for patients with chronic heart failure in the community. The importance of a disease management program. *Chest* 2002;122:906-12.
- Aldana SG, Whitmer WR, Greenlaw R, Avins AL, Salberg A, Barnhurst M, et al. Cardiovascular risk reductions associated with aggressive lifestyle modification and cardiac rehabilitation. *Heart Lung* 2003 Nov-Dec;32(6):374-82.
- Ammerman AS, Keyserling TC, Atwood JR, Hosking JD, Zayed H, Krasny C. A randomized controlled trial of a public health nurse directed treatment program for rural patients with high blood cholesterol. *Prev Med* 2003 Mar;36(3):340-51.
- Angerer P, Siebert U, Kothny W, Muhlbauer D, Mudra H, von Schacky C. Impact of social support, cynical hostility and anger expression on progression of coronary atherosclerosis. *J Am Coll Cardiol* 2000 Nov 15;36(6):1781-8.
- Anonymous. The Roman coronary heart disease prevention program. Final results. *Giornale Italiano di Cardiologia* 1982;12:541-54.
- Ariyo AA, Haan M, Tangen CM, Rutledge JC, Cushman M, Dobs A, et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. *Circulation* 2000 Oct 10;102(15):1773-9.
- Arthur HM, Daniels C, McKelvie R, Hirsh J, Rush B. Effect of a preoperative intervention on preoperative and postoperative outcomes in low-risk patients awaiting elective coronary artery bypass graft surgery. A randomized, controlled trial. *Ann Intern Med* 2000 Aug 15;133(4):253-62.
- Barnard RJ, Massey MR, Cherny S, O'Brien LT, Pritikin N. Long-term use of a high-complex-carbohydrate, high-fiber, low-fat diet and exercise in the treatment of NIDDM patients. *Diabetes Care* 1983 May-Jun;6(3):268-73.
- Barnes VA, Treiber FA, Turner JR, Davis H, Strong WB. Acute effects of transcendental meditation on hemodynamic functioning in middle-aged adults. *Psychosom Med* 1999 Jul-Aug;61(4):525-31.
- Bartels C, Gerdes A, Babin-Ebell J, Beyersdorf F, Boeken U, Doenst T, et al. Working Group on Extracorporeal Circulation and Mechanical Ventricular Assist Devices of the German Society for Thoracic and Cardiovascular Surgery.

Cardiopulmonary bypass: Evidence or experience based? *J Thorac Cardiovasc Surg* 2002 Jul;124(1):20-7.

Beckie T. A supportive-educative telephone program: Impact on knowledge and anxiety after coronary artery bypass graft surgery. *Heart Lung* 1989;18:46-55.

Bennett P, Blackall M, Clapham M, Little S, Player D, Williams K. South Birmingham Coronary Prevention Project: a district approach to the prevention of heart disease. *Community Medicine* 1989;11:90-6.

Bentsson K. Rehabilitation after myocardial infarction. A controlled study. *Scan J Rehab Med* 1983;15:1-9.

Berglund G, Nilsson P, Ericksson KF, et al. Long-term outcome of the Malmo preventive project: mortality and cardiovascular morbidity. *J Intern Med* 2000;247:19-29.

Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Enhancing Recovery in Coronary Heart Disease Patients Investigators (ENRICHD). Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. *JAMA* 2003 Jun 18;289(23):3106-16.

Bethell HJ, Mullee MA. A controlled trial of community based coronary rehabilitation. *Br Heart J* 1990;64:370-5.

Billings JH, Scherwitz LW, Sullivan R, Sparler S, Ornish DM. Group support therapy in the Lifestyle Heart Trial. In: Scheidt S, Allan R, eds. *Heart and Mind: The Emergence of Cardiac Psychology*. Washington, DC: American Psychological Association 1996:233-52.

Bjarnason-Wehrens B, Benesch L, Bischoff KO, Buran-Kilian B, Gysan D, Hollenstein U, et al. Effects of a Phase II Cardiac Rehabilitation Program Performed on an Outpatient Basis. *Herz* 2003 Aug; 28(5):404-412.

Blair TP, Bryant FJ, Bocuzzi S. Treatment of hypercholesterolemia by a clinical nurse using a stepped-care protocol in a non-volunteer population. *Arch Intern Med* 1988;148:1046-8.

Blumenthal JA, Jiang W, Babyak MA, Krantz DS, Frid DJ, Coleman RE, et al. Stress management and exercise training in cardiac patients with myocardial ischemia. Effects on prognosis and evaluation of mechanisms. *Arch Intern Med* 1997 Oct 27;157(19):2213-23.

- Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. *J Gen Intern Med* 1997;12:158-64.
- Boulay P, Prud'homme D. Health-Care Consumption and Recurrent Myocardial Infarction After 1 Year of Conventional Treatment Versus Short- and Long-Term Cardiac Rehabilitation. *Preventive Medicine* 2004 May; 38(5):586-593.
- Bramlet DA, King H, Young L, Witt JR, Stoukides CA, Kaul AF. Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. *Am J Cardiol* 1997;80(8B):39H-44H.
- Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. *N Engl J Med* 2001 Nov 29;345(22):1583-92.
- Burell G. Behavioral medicine interventions in secondary prevention of coronary heart disease. In: K. Orth-Gomer & N. Schneiderman (Eds.), *Behavioral Medicine Approaches to Cardiovascular Disease Prevention* 1996; 227-236.
- Cambien F, Richard JL, Ducimetiere P, Warnet JM, Kahn J. The Paris Cardiovascular Risk Factor Prevention Trial. Effects of two years of intervention in a population of young men. *J Epid Comm Health* 1981;35:91-7.
- Campbell NC, Ritchie LD, Thain J, Deans HG, Rawles JM, Squair JL. Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. *Heart* 1998 Nov;80(5):447-52.
- Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004 Apr 8;350(15):1495-504.
- Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease. Long-term CASS experience. *Circulation* 1995 May 1;91(9):2325-34.
- Carlson JJ, Johnson JA, Franklin BA, Vanderlaan RL. Program Participation, Exercise Adherence, Cardiovascular Outcomes, and Program Cost of Traditional Versus Modified Cardiac Rehabilitation. *American Journal of Cardiology* 2000 Jul 1; 86(1):17-23.
- Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, et al. Depression, heart rate variability, and acute myocardial infarction. *Circulation* 2001 Oct 23;104(17):2024-8.

Castillo-Richmond A, Schneider RH, Alexander CN, Cook R, Myers H, Nidich S, et al. Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans. *Stroke* 2000 Mar;31(3):568-73.

Chinaglia A, Gaschino G, Asteggiano R, Titta G, Gullstrand R, Bobbio M, et al. Impact of a nurse-based heart failure management program on hospitalization rate, functional status, quality of life, and medical costs. *Ital Heart J* 2002;3:532-8.

Clark MA, Bakhai A, Lacey MJ, Pelletier EM, Cohen DJ. Clinical and economic outcomes of percutaneous coronary interventions in the elderly: an analysis of medicare claims data. *Circulation* 2004 Jul 20;110(3):259-64.

Coleman EA, Grothaus LC, Sandhu N, Wagner EH. Chronic care clinics: a randomized controlled trial of a new model of primary care for frail older adults. *J Am Geriatr Soc* 1999;47:775-83.

Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. *Circulation* 2002 Dec 3;106(23):2884-7.

Coull AJ, Taylor VH, Elton R, Murdoch PS, Hargreaves AD. A randomised controlled trial of senior Lay Health Mentoring in older people with ischaemic heart disease: The Braveheart Project. *Age Ageing*. 2004 Jul;33(4):348-54.

Council on Clinical Cardiology and Council on Nutrition, Physical Activity and Metabolism. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). *Circulation* 2003 Jun 24;107(24):3109-16.

Cummings JE, Hughes SL, Weaver FM, et al. Cost-effectiveness of Veterans Administration hospital-based home care. *Arch Intern Med* 1990;150:1274-80.

Cundiff DK. Coronary artery bypass grafting (CABG): reassessing efficacy, safety, and cost. *MedGenMed* 2002 Jun 19;4(2):7.

DeBusk RF, Haskell WL, Miller NH, Berra K, Taylor CB, Berger WE, et al. Medically directed at-home rehabilitation soon after clinically uncomplicated acute myocardial infarction: a new model for patient care. *Am J Cardiol* 1985;55:251-7.

Debusk RF, Miller NH, Parker KM, Bandura A, Kraemer HC, Cher DJ, et al. Care Management for Low-Risk Patients With Heart Failure - a Randomized, Controlled Trial. *Annals of Internal Medicine* 2004 Oct 19; 141(8):606-613.

de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999 Feb 16;99(6):779-85.

Denollet J, Brutsaert DL. Reducing emotional distress improves prognosis in coronary heart disease: 9-year mortality in a clinical trial of rehabilitation. *Circulation* 2001 Oct 23;104(17):2018-23.

Detry JMR, Vierendeel IA, Vanbutsele RJ, Robert AR. Early Short-Term Intensive Cardiac Rehabilitation Induces Positive Results as Long as One Year After the Acute Coronary Event: a Prospective One-Year Controlled Study. *Journal of Cardiovascular Risk* 2001 Dec; 8(6):355-361.

DeVries A, Day B, Scott D. Financial impact of the Dr. Dean Ornish program for reversing heart disease. In: *Medical Management Analysis; Highmark Blue Cross Blue Shield; June 2003.*

DeVries A, Palmer A, Scheib C, Day B, Bennett S, Fetterolf D, et al. Financial impact of the Dr. Dean Ornish program for reversing heart disease. In: *Medical Management Analysis; Highmark Blue Cross Blue Shield; 2002 February 14;4(3).*

Diehl HA. Coronary risk reduction through intensive community-based lifestyle intervention: the Coronary Health Improvement Project (CHIP) experience. *Am J Cardiol* 1998 Nov 26;82(10B):83T-87T.

Dugan E, Cohen SJ. Improving physicians' implementation of clinical practice guidelines: enhancing primary care practice. In Shumaker SA, Schron EB, Ockene JK, McBee WL (Eds.). *The handbook of health behavior change – second edition (pp. 283-304) Springer Publishing Company, 1998.*

Dugmore LD, Tipson RJ, Phillips MH, Flint EJ, Stentiford NH, Bone MF, et al. Changes in cardiorespiratory fitness, psychological wellbeing, quality of life, and vocational status following a 12 month cardiac exercise rehabilitation programme. *Heart* 1999;81:359-66.

Eaker ED, Sullivan LM, Kelly-Hayes M, D'Agostino RB Sr, Benjamin EJ. Anger and hostility predict the development of atrial fibrillation in men in the Framingham Offspring Study. *Circulation* 2004 Mar 16;109(10):1267-71.

Eddy DM. Assessment of intensive lifestyle changes for the treatment of coronary heart disease. July 12, 2000.

Ellingsen I, Hjermmann I, Abdelnoor M, Hjerkmann EM, Tonstad S. Dietary and antismoking advice and ischemic heart disease mortality in men with normal or high fasting triacylglycerol concentrations: a 23-y follow-up study. *American Journal of Clinical Nutrition* 2003 Nov; 78(5):935-40.

Elliott-Eller M, Weidner G, Pischke C, Marlin R, Li M, Mendell N, et al. Clinical events in heart disease patients with low left ventricular ejection fraction: 3 year follow-up results. *Proceedings of the International Academy of Cardiology, 3rd World Congress on Heart Disease – New trends in Research, Diagnosis and Treatment*; 2003 July; Washington DC, USA.

Engblom E, Korpilahti K, Hamalainen H, Ronnema T, Puukka P. Quality of life and return to work 5 years after coronary artery bypass surgery. Long-term results of cardiac rehabilitation. *J Cardiopulm Rehabil* 1997;17:29-36.

Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. *Circulation* 2004 Jul 13;110(2):214-9. Epub 2004 Jun 14.

Esselstyn CB Jr. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease (an overdue requiem for palliative cardiology). *Am J Cardiol* 1999 Aug 1;84(3):339-41, A8.

Family Heart Study Group. Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. *BMJ* 1994;308:313-20.

Fields JZ, Walton KG, Schneider RH, Nidich S, Pomerantz R, Suchdev P, et al. Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of Maharishi Vedic Medicine. *Am J Cardiol* 2002 Apr 15;89(8):952-8.

Flanagan DE, Cox P, Paine D, Davies J, Armitage M. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. *QJM* 1999;92:245-50.

Frasure-Smith N, Prince R. The ischemic heart disease life stress monitoring program: impact on mortality. *Psychosomatic Med* 1985;47:431-45.

Frasure-Smith N, Lesperance F, Gravel G, Masson A, Juneau M, Talajic M, et al. Social support, depression, and mortality during the first year after myocardial infarction. *Circulation* 2000 Apr 25;101(16):1919-24.

Friedman M, Thoreson C, Gill J, et al. Alteration of type A behavior and reduction in cardiac recurrences in post-myocardial infarction patients. *Am Heart J* 1984;108:237-48.

Galatius S, Gustafsson F, Kistorp CM, Nielsen PH, Atar D, Hildebrandt PR. Establishment of a nurse-led heart failure clinic. Design and baseline data from the first two years. *Ugeskr Laeger* 2003;165:686-90.

Geil PB, Anderson JW, Gustafson NJ. Women and men with hypercholesterolemia respond similarly to an American Heart Association step 1 diet. *J Am Diet Assoc* 1995 Apr;95(4):436-41.

George BJ, Goldberg N. The benefits of exercise in geriatric women. *Am J Geriatr Cardiol* 2001 Sep-Oct;10(5):260-3.

Ghoncheh S, Smith JC. Progressive muscle relaxation, yoga stretching, and ABC relaxation theory. *J Clin Psychol* 2004 Jan;60(1):131-6.

Gielen S, Schuler G, Hambrecht R. Exercise training in coronary artery disease and coronary vasomotion. *Circulation* 2001 Jan 2;103(1):E1-6.

Gleason JA, Bourdet KL, Koehn K, Holay SY, Schaefer EJ. Cardiovascular risk reduction and dietary compliance with a home-delivered diet and lifestyle modification program. *J Am Diet Assoc* 2002 Oct;102(10):1445-51.

Gould KL, Ornish D, Kirkeeide R, Brown S, Stuart Y, Buchi M, et al. Improved stenosis geometry by quantitative coronary arteriography after vigorous risk factor modification. *Am J Cardiol* 1992 Apr 1;69(9):845-53.

Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. *JAMA* 1995 Sep 20;274(11):894-901.

Grimm RH Jr., for the MRFIT. The Multiple Risk Factor Intervention Trial in the US. A summary of results at four years in special intervention and usual care men. *Preventive Medicine* 1983;12:185-90.

Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004 Jul 13;110(2):227-39.

Gulati M, Pandey DK, Arnsdorf MF, Lauderdale DS, Thisted RA, Wicklund RH, et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. *Circulation* 2003 Sep 30;108(13):1554-9.

Hakim AA, Curb JD, Petrovitch H, Rodriguez BL, Yano K, Ross GW, et al. Effects of walking on coronary heart disease in elderly men: the Honolulu Heart Program. *Circulation* 1999 Jul 6;100(1):9-13.

Hambrecht R, Walther C, Mobius-Winkler S, Gielen S, Linke A, Conradi K, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. *Circulation* 2004 Mar 23;109(11):1371-8. Epub 2004 Mar 08.

Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary clinic compared with primary physician management. *Am J Cardiol* 1998;81:929-33.

Hedback B, Perk J. 5-year results of a comprehensive rehabilitation programme after myocardial infarction. *Eur Heart J* 1987;8:234-42.

Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK Study. *BMJ* 1995;310:1099-1104.

Jain SC, Uppal A, Bhatnagar SO, Talukdar B. A study of response pattern of non-insulin dependent diabetics to yoga therapy. *Diabetes Res Clin Pract* 1993 Jan;19(1):69-74.

Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). *Circulation* 1995 May 15;91(10):2528-40.

Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. *Circulation* 1994 Nov;90(5):2225-9.

Ketola E, Makela M, Klockars M. Individualised Multifactorial Lifestyle Intervention Trial for High-Risk Cardiovascular Patients in Primary Care. *British Journal of General Practice* 2001 Apr;51(465):291-294.

Koertge J, Weidner G, Billings JH, Elliott-Eller M, Lipsenthal L, Merritt-Worden T, et al. Medical and psychosocial characteristics of CHD patients in the Multicenter Lifestyle Demonstration Project: Results from a 1-year follow-up [Abstract]. *Psychosomatic Medicine* 2002;64:85-174.

Koertge J, Weidner G, Elliott-Eller M, Scherwitz L, Merritt-Worden TA, Marlin R, et al. Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project. *Am J Cardiol* 2003 Jun 1;91(11):1316-22.

Kornitzer M, De Backer G, Dramaix M, Thilly C. The Belgian Heart Disease Prevention Project. Modification of the coronary risk profile in an industrial population. *Circulation* 1980;61:18-25.

Krachler M, Lindschinger M, Eber B, Watzinger N, Wallner S. Trace elements in coronary heart disease: Impact of intensified lifestyle modification. *Biol Trace Elem Res* 1997 Dec;60(3):175-85.

Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. *Circulation* 2002 Nov 19;106(21):2747-57.

Lampert R, Joska T, Burg MM, Batsford WP, McPherson CA, Jain D. Emotional and physical precipitants of ventricular arrhythmia. *Circulation* 2002 Oct 1;106(14):1800-5.

Lear SA, Ignaszewski A, Linden W, Brozic A, Kiess M, Spinelli JJ, et al. A randomized controlled trial of an extensive lifestyle management intervention (ELMI) following cardiac rehabilitation: study design and baseline data. *Curr Control Trials Cardiovasc Med* 2002 Nov 12;3(1):9.

Lesperance F, Frasure-Smith N, Talajic M, Bourassa MG. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. *Circulation* 2002 Mar 5;105(9):1049-53.

Lewin RJ, Furze G, Robinson J, Griffith K, Wiseman S, Pye M, et al. A randomised controlled trial of a self-management plan for patients with newly diagnosed angina. *Br J Gen Pract* 2002 Mar;52(476):194-6, 199-201.

Lewis CE, Resnik BA. Nurse clinics and progressive ambulatory patient care. *N Engl J Med* 1967;277:1236-41.

Liao XX, Ma H, Dong YG, Tang AL, Tao J, Yang XQ. Effects of early rehabilitative intervention on heart rate variability and quality of life in patients with uncomplicated acute myocardial infarction. *Zhonghua Linchuang Kangfu Zazhi* 2003;7(21):2934-2935.

Lichtenstein AH, Van Horn L. Very low fat diets. *Circulation* 1998 Sep 1;98(9):935-9.

Lindholm LH, Ekblom T, Dash C, Eriksson M, Tibblin G, Schersten B on behalf of the CELL Study Group. The impact of health care advice given in primary care on cardiovascular risk. *BMJ* 1995;310:1105-9.

Maggioni AP. Secondary prevention: improving outcomes following myocardial infarction. *Heart* 2000 Sep;84 Suppl 1:i5-7:discussion i50.

Malach M, Imperato PJ. Depression and acute myocardial infarction. *Prev Cardiol* 2004 Spring;7(2):83-90.

Marra S, Paolillo V, Spadaccini F, Angelino PF. Long-term follow-up after a controlled randomized post-myocardial infarction rehabilitation programme: effects on morbidity and mortality. *Eur Heart J* 1985;6:656-63.

Marshall J, Penckofer S, Llewellyn J. Structured postoperative teaching and knowledge and compliance of patients who had coronary artery bypass surgery. *Heart Lung* 1986;15:76-82.

Matthews KA, Gump BB, Harris KF, Haney TL, Barefoot JC. Hostile behaviors predict cardiovascular mortality among men enrolled in the Multiple Risk Factor Intervention Trial. *Circulation* 2004 Jan 6;109(1):66-70.

Meer H. Coronary heart disease health improvement programme. Final report. Barking and Havering Health Authority, Romford (United Kingdom). Directorate of Public Health, Oct 1999. 67 p. Available from British Library Document Supply Centre-DSC:6966.200(120) In: Public health research report No. 120.

Meland E, Laerum E, Ulvik RJ. Effectiveness of two preventive interventions for coronary heart disease in primary care. *Scand J Prim Health Care* 1997;15:57-64.

Merritt TA, Scherwitz LW, Brown SE, Billings JH, Armstrong WT, Sparler SL, et al. Changes in lifestyle and exercise capacity. *Journal of Cardiopulmonary Rehabilitation* 1990;10(9):354.

Merritt T, Ornish D, Scherwitz L, Billings J, Elliott L, Lipsenthal L, et al. Effects of intensive lifestyle changes on coronary heart disease risk factors and clinical status in self-selected heart patients. *Journal of Cardiopulmonary Rehabilitation* 1995;15(5):353.

Merritt T, Ornish D, Scherwitz L, Billings J, Elliott L, Lipsenthal L, et al. Preliminary results from the multicenter lifestyle trial: Can self-selected heart patients maintain intensive lifestyle changes? *Journal of Cardiopulmonary Rehabilitation* 1995;15(5):354.

Merritt-Worden TA, Pettengill EB, Ornish D. Gender comparisons in an intensive comprehensive risk factor reduction program [Abstract]. *Journal of Cardiopulmonary Rehabilitation* 2003;23(5):376.

Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). *Circulation* 1997 Dec 16;96(12):4211-8.

Miller ER 3rd, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, et al. Results of the Diet, Exercise, and Weight Loss Intervention Trial (DEW-IT). *Hypertension* 2002 Nov;40(5):612-8.

Mittleman MA, Maclure M, Sherwood JB, Mulry RP, Tofler GH, Jacobs SC, et al. Triggering of acute myocardial infarction onset by episodes of anger. Determinants of Myocardial Infarction Onset Study Investigators. *Circulation* 1995 Oct 1;92(7):1720-5.

National Cholesterol Education Program (NCEP). Detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Final Report. Third Report of the National Cholesterol Education Program (NCEP), National Heart, Lung, and Blood Institute, National Institutes of Health, NIH Publication No. 02-5215, September 2002.

Ness AR, Hughes J, Elwood PC, Whitley E, Smith GD, Burr ML. The long-term effect of dietary advice in men with coronary disease: follow-up of the Diet and Reinfarction trial (DART). *European Journal of Clinical Nutrition* 2002 Jun;56(6):512-8.

Nicholson AS, Sklar M, Barnard ND, Gore S, Sullivan R, Browning S. Toward improved management of NIDDM: A randomized, controlled, pilot intervention using a lowfat, vegetarian diet. *Prev Med* 1999 Aug;29(2):87-91.

Oldenburg B, Martin A, Greenwood J, Bernstein L, Allan R. A controlled trial of a behavioral and educational intervention following coronary artery bypass surgery. *J Cardiopulmonary Rehabil* 1995;15:39-46.

Ornish D. Avoiding revascularization with lifestyle changes: The Multicenter Lifestyle Demonstration Project. *Am J Cardiol* 1998 Nov 26;82(10B):72T-76T.

Ornish D. Statins and the soul of medicine. *American Journal of Cardiology* 2002;89(1):1286-90.

Ornish DM, Pettengill EB. Marked improvements in biomedical and psychosocial cardiac risk factors from a community-based lifestyle change program. *Proceedings of the Annual Meeting of the American Heart Association*, 2003.

Ornish D. Concise Review: intensive lifestyle changes in the management of coronary heart disease. Concise review related to chapter 241: the pathogenesis of atherosclerosis. Printed from Harrison's Online (www.harrisononline.com). McGraw-Hill Companies, 2001-2004 (http://www.accessmedicine.com/server-java/arknoid/amed/harrisons/ex_editorials/ed1209... accessed 09 Dec 2004).

Ornish D. Intensive life-style changes in the management of coronary heart disease (chapter 8). In: Braunwald E. Harrison's Advances in Cardiology. New York: McGraw Hill, 2002.

Ornish D, Hart JA. Intensive Risk Factor Modification. In: Hennekens C, Manson J, eds. Clinical Trials in Cardiovascular Disease. Boston: W.B. Sanders, 1998.

Pater C, Ditlef Jacobsen C, Rollag A, Sandvik L, Erikssen J, Karin Kogstad E. Design of a randomized controlled trial of comprehensive rehabilitation in patients with myocardial infarction, stabilized acute coronary syndrome, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting: Akershus Comprehensive Cardiac Rehabilitation Trial (the CORE Study). *Curr Control Trials Cardiovasc Med* 2000;1(3):177-183.

Peiss B, Kurlito B, Rubenfire M. Physicians and nurses can be effective educators in coronary risk reduction. *J Gen Intern Med* 1995;10:77-81.

Pettengill EB, Pearson J, Pifalo B, Wilhelm A, Lipsenthal L, Merritt T et al. Community-based lifestyle change program produces substantial reduction in biomedical and psychosocial cardiac risk factors. 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13-14, 2002; Washington, DC.

Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, et al; Trial of Invasive versus Medical therapy in Elderly patients (TIME) Investigators. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. *JAMA* 2003 Mar 5;289(9):1117-23.

Picard MH, Schwartz DC, Ahn DK, Kraemer HC, Berger WE, Blumberg R, et al. Cost-benefit analysis of early return to work after uncomplicated acute myocardial infarction. *Am J Cardiol* 1989;63:1308-14.

Pischke C, Weidner G, Billings J, Elliott-Eller M, Lipsenthal L, Merritt-Worden T, et al. Lifestyle changes among heart disease patients with diabetes: results from the multicenter lifestyle demonstration project. Proceedings of the 62nd Annual Meeting & Scientific Sessions of the American Diabetes Association; 2002 June 14-18; San Francisco, USA.

Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. *N Engl J Med* 1999 Jul 8;341(2):70-6.

Pollock ML, Franklin BA, Balady GJ, Chaitman BL, Fleg JL, Fletcher B, et al. AHA Science Advisory. Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: An advisory from the Committee on Exercise, Rehabilitation, and Prevention, Council on Clinical Cardiology, American Heart Association; Position paper endorsed by the American College of Sports Medicine. *Circulation* 2000 Feb 22;101(7):828-33.

Pozen MW, Stechmiller JA, Harris W, Smith S, Fried DD, Voigt GC. A nurse rehabilitator's impact on patients with myocardial infarction. *Medical Care* 1977;15:830-7.

Prochaska JO, Johnson S, Lee P. The transtheoretical model of behavior change. In Shumaker SA, Schron EB, Ockene JK, McBee WL (Eds.), *The handbook of health behavior change – second edition* (pp. 59-84) Springer Publishing Company.

Pyke SDM, Wood DA, Kinmonth AL, Thompson SG, for the Family Heart Study Group. Change in coronary risk and coronary risk factor levels in couples following lifestyle intervention. *Arch Fam Med* 1997;6:354-60.

Rahe RH, Ward HW, Hayes V. Brief group therapy in myocardial infarction rehabilitation: three- to four-year follow-up of a controlled trial. *Psychosomatic Med* 1979;41:229-

Rihal CS, Raco DL, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. *Circulation* 2003 Nov 18;108(20):2439-45.

Roderick P, Ruddock V, Hunt P, Miller G. A randomized trial to evaluate the effectiveness of dietary advice by practice nurses in lowering diet-related coronary heart disease risk. *Br J Gen Pract* 1997;47:7-11.

Roman O, Gutierrez M, Luksic I, Chavez E, Camuzzi AL, Villalon E, et al. Cardiac rehabilitation after acute myocardial infarction. 9-year controlled follow-up study. *Cardiology* 1983;70:223-31.

Rose G, Heller RF, Pedoe HT, Christie DGS. Heart disease prevention project: a randomised controlled trial in industry. *BMJ* 1980;i:747-751.

Rubenstein LV, Kahn KL, Reinisch EJ, Sherwood MJ, Rogers WH, Kamberg C, et al. Changes in quality of care for five diseases measured by implicit review, 1981 to 1986. *JAMA* 1990 Oct 17;264(15):1974-9.

Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. *JAMA* 2003 Jul 9;290(2):215-21.

[No authors listed] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). *Lancet* 1994 Nov 19;344(8934):1383-9.

Schectman G, Wolff N, Byrd JC, Hiatt JG, Hartz A. Physician extenders for cost-effective management of hypercholesterolemia. *J Gen Intern Med* 1996;11:277-86.

Schneider RH, Stagers F, Alexander CN, Sheppard W, Rainforth M, Kondwani K, et al. A randomised controlled trial of stress reduction for hypertension in older African Americans. *Hypertension* 1995 Nov;26(5):820-7.

Sdringola S, Nakagawa K, Nakagawa Y, Yusuf SW, Boccalandro F, Mullani N, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. *J Am Coll Cardiol* 2003 Jan 15;41(2):263-72.

Shaffer J, Wexler LF. Reducing low-density lipoprotein cholesterol levels in an ambulatory care system. Results of a multidisciplinary collaborative practice lipid clinic compared with traditional physician-based care. *Arch Intern Med* 1995;155:2330-5.

Shintani TT, Beckham S, Brown AC, O'Connor HK. The Hawaii Diet: ad libitum high carbohydrate, low fat multi-cultural diet for the reduction of chronic disease risk factors: obesity, hypertension, hypercholesterolemia, and hyperglycemia. *Hawaii Med J* 2001 Mar;60(3):69-73.

Simpson DR, Dixon BG, Bolli, P. Effectiveness of Multidisciplinary Patient Counselling in Reducing Cardiovascular Disease Risk Factors Through Nonpharmacological Intervention: Results From the Healthy Heart Program. *Canadian Journal of Cardiology* 2004 Feb;20(2):177-186.

Sivarajan ES, Newton KM, Almes MJ, Kempf TM, Mansfield LW, Bruce RA. Limited effects of outpatient teaching and counseling after myocardial infarction: a controlled study. *Heart Lung* 1983;12:65-73.

The South-East London Screening Study Group. A controlled trial of multiphasic screening in middle-age: results of the South-East London Screening Study. *Int J Epidemiol* 1977;6:357-63.

Specchia G, De Servi S, Scire A, et al. Interaction between exercise training and ejection fraction in predicting prognosis after a first myocardial infarction. *Circulation* 1996;94:978-82.

Stahle A, Mattsson E, Ryden L, Unden A, Nordlander, R. Improved physical fitness and quality of life following training of elderly patients after acute coronary events. A 1 year follow-up randomized controlled study.[see comment]. *European Heart Journal* 1999 Oct;20(20):1475-84.

Starkey C, Michaelis J, Lusignan S. Computerised systematic secondary prevention in ischemic heart disease: a study in one practice. *Public Health* 2000;114:169-75.

Stern MJ, Cleary P. The national exercise and heart disease project. Long-term psychosocial outcome. *Arch Intern Med* 1982;142:1093-7.

Strandberg TE, Pitkala K, Berglind S, Nieminen MS, Tilvis RS. Multifactorial cardiovascular disease prevention in patients aged 75 years and older: A randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. *Am Heart J* 2001 Dec;142(6):945-51.

Taddei S, Galetta F, Viridis A, Ghiadoni L, Salvetti G, Franzoni F, et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. *Circulation* 2000 Jun 27;101(25):2896-901.

Thoresen CE, Friedman M, Gill JK, Ulmer DK. The recurrent coronary prevention project. Some preliminary findings. *Acta Med Scand* 1982;660(Suppl):172-92.

Townsend J, Piper M, Frank AO, Dyer S, North WRS, Meade TW. Reduction in hospital readmission stay of elderly patients by a community based hospital discharge scheme: a randomized controlled trial. *BMJ* 1988;297:544-7.

Tu JV, Pashos CL, Naylor CD, Chen E, Normand SL, Newhouse JP, et al. Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. *N Engl J Med* 1997 May 22;336(21):1500-5.

Vale MJ, Jelinek MV, Best JD, Dart AM, Grigg LE, Hare DL, et al; COACH Study Group. Coaching patients On Achieving Cardiovascular Health (COACH): a multicenter randomized trial in patients with coronary heart disease. *Arch Intern Med* 2003 Dec 8-22;163(22):2775-83.

Van Drenth BB, Hulscher EJJ, Mookink HGA, van de Lisdonk EH, van der Wouden JC, Grol RPTM. Effects of outreach visits by trained nurses on cardiovascular risk-factor recording in general practice. A controlled trial. *Eur J Gen Pract* 1997;3:90-5.

Vedin A, Wilhelmsson C, Tibblin G, Wilhelmsen L. The postinfarction clinic in Goteborg, Sweden. *Acta Med Scand* 1976;200:453-6.

von Birgelen C, Hartmann M, Mintz GS, Baumgart D, Schmermund A, Erbel R. Relation between progression and regression of atherosclerotic left main coronary artery disease and serum cholesterol levels as assessed with serial long-term (> or =12 months) follow-up intravascular ultrasound. *Circulation* 2003 Dec 2;108(22):2757-62.

Wallner S, Watzinger N, Lindschinger M, Smolle KH, Toplak H, Eber B, et al. Effects of intensified lifestyle modification on the need for further revascularization after coronary angioplasty.[see comment]. *European Journal of Clinical Investigation* 1999 May;29(5):372-9.

Wasson J, Gaudette C, Whaley F, Sauvigne A, Baribeau P, Welch G. Telephone care as a substitute for routine clinic follow-up. *JAMA* 1992;267:1788-93.

Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. *Circulation* 1994 Mar;89(3):959-68.

Weber F, Barnard RJ, Roy D. Effects of a high-complex-carbohydrate, low-fat diet and daily exercise on individuals 70 years of age and older. *J Gerontol* 1983 Mar;38(2):155-61.

Weidner G, Pischke C, Eller M, Ornish D. Clinical profile and outcome of heart disease patients with low LVEF: results from the Multicenter Lifestyle Demonstration Project. Presented at the annual meeting of the American Psychosomatic Society, Phoenix, AZ, March 5-8, 2003.

Weinberger M, Smith DM, Katz BP, Moore PS. The cost-effectiveness of intensive post-discharge care: a randomized trial. *Med Care* 1988;26:1092-1102.

Weingarten S, Reidinger M, Conner L, Johnson B, Ellrodt AG. Reducing lengths of stay in the coronary care unit with a practice guideline for patients with congestive heart failure: Insights from a controlled clinical trial. *Med Care* 1994;32:1232-43.

Weintraub WS, Clements SD Jr, Crisco LV, Guyton RA, Craver JM, Jones EL, et al. Twenty-year survival after coronary artery surgery: an institutional perspective from Emory University. *Circulation* 2003 Mar 11;107(9):1271-7.

Williams JE, Paton CC, Siegler IC, Eigenbrodt ML, Nieto FJ, Tyroler HA. Anger proneness predicts coronary heart disease risk: prospective analysis from the atherosclerosis risk in communities (ARIC) study. *Circulation* 2000 May 2;101(17):2034-9.

Woollard J, Burke V, Beilin LJ, Verheijden M, Bulsara MK. Effects of a general practice-based intervention on diet, body mass index and blood lipids in patients at cardiovascular risk. *Journal of Cardiovascular Risk* 2003 Feb;10(1):31-40.

Woollard J, Burke V, Beilin LJ. Effects of General Practice-Based Nurse-Counselling on Ambulatory Blood Pressure and Antihypertensive Drug Prescription in Patients at Increased Risk of Cardiovascular Disease. *Journal of Human Hypertension* 2003 Oct; 17(10):689-695.

Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999 Apr;69(4):632-46.

Appendix C: Copy of questions sent to primary study authors

Secondary Prevention Review:

Paper Title:

Year:

First author:

1. Program type CCR CR IC

2. Location Res Hospital GP Comm Home Comb.

Author query: Where was the main location of the program?

3. Commencement after index event _____ weeks
Author query: What was the mean time between index clinical event and program commencement?

4. Mean Length _____ weeks
Author query: What was the mean length of the program?

5. Number sessions per pt _____ sessions Unclear
Author query: What was the total number of hours patients should participate in the program?

6. Physician involvement Unclear None Yes
 specify: _____
Author query: How were physicians involved in the program?

7. Theoretical basis Unclear None Yes
 specify: _____
Author query: Was the program based on any stated behavioural change theory? If so, what type?

8. Individualization Unclear
 Standardized components and content
 Individualization as *per usual care*
 Individualized components and standardized content
 Individualized components and individualized content

Author query : How was the program individualized for each patient (if at all)?

9. Miscellaneous facets & features Unclear No Yes
1) Nurse prescribing
2) Supplementary pt telephone support
3) Specialist CR/cardiac profs
4) Based on stated guidelines

Author queries:

Did the program involve any nurse or pharmacist prescribing / telephone support?

Did the program involve specialists in cardiology or rehabilitation?

Was the program based on any stated clinical guidelines?

Appendix D: Missing fields prior to and after author survey

Unclear variables	Prior to survey	After survey
Location of program	3	3
Commencement	10	3
Program length	5	1
Session total	17	8
Physician Involvement	6	0
Theoretical Basis	2	0
Individualization	2	1
Nurse / Pharm Prescribing	2	0
Telephone Support	1	1
Specialist input	7	2
Guidelines	2	2
<i>Total missing fields</i>	<i>57</i>	<i>21</i>

Appendix E: Results of descriptive survey

Physician Involvement	Number of Studies (%)
None	8 (17%)
ETT / Exercise Supervision	24 (52%)
Follow up	5 (11%)
Coordination	4 (9%)
Lipid Management	1 (2%)
Screening for Inclusion	2 (4%)
Teaching	2 (4%)

Theoretical Basis	Number of Studies n=46 (%)
None	39 (85%)
Social Cognitive / Learning	2 (4%)
Cognitive Behavioral / Motivation	3 (7%)
Behavioral	2 (4%)

Individualization	Number of Studies n=46 (%)
Unclear	1 (2%)
Standardized components and contents	14 (30%)
Individualized as per usual care	20 (43%)
Individualized components or individualized contents	6 (13%)
Individualized components and individualized contents	5 (10%)

Nurse Prescribing	Number of Studies n=46 (%)
No	40 (87%)
Yes	6 (13%)

Phone Support	Number of Studies n=46 (%)
0. Unclear	1 (2%)
1. No	27 (59%)
2. Yes	18 (39%)

Specialist CR / Cardiac Professionals	Number of Studies n=46 (%)
Unclear	2 (4%)
No	7 (17%)
Yes	37 (79%)

Based on Stated Guidelines	Number of Studies n=46 (%)
Unclear	2 (4%)
No	34 (72%)
Yes	10 (23%)